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Palavras-chave – Células estaminais cancerígenas, cancro de pulmão, quimio-
resistência 
Resumo  
A resistência tumoral é o maior problema relacionado com a eficácia do tratamento 
de cancro de pulmão, tipo de cancro com a maior taxa de mortalidade a nível mundial. 
Atualmente, acredita-se que uma subpopulação de células tumorais, as células estaminais 
cancerígenas (CECs) que possuem capacidade de autorrenovação e capacidade de sustentar 
o crescimento tumoral, seja parcialmente responsável pela resistência tumoral face à 
terapia. De facto, CECs pulmonares isoladas de tumores de pacientes com cancro de 
pulmão revelaram-se particularmente químio-resistentes. Embora os mecanismos 
subjacentes à resistência não serem completamente compreendidos, a sobre-expressão de 
bombas de efluxo, de proteínas anti-apoptóticas e alta eficiência na reparação do ADN 
parecem fazer parte das propriedades das CECs responsáveis pela resistência aos agentes 
químio-terapêuticos.  
 É pretendido, neste projeto, isolar e caracterizar populações de CECs pulmonares e, 
tendo em conta os seus mecanismos de resistência, identificar possíveis alvos terapêuticos 
de forma a sensibilizá-las aos fármacos atualmente utilizados clinicamente.  
Linhas celulares pulmonares cancerígenas (NCI-H460, A549) foram incubadas com 
os fármacos cisplatina ou doxorrubicina durante três semanas, seguindo-se um período de 
recuperação, para isolar uma possível população de CECs. Durante este período, a 
morfologia celular foi acompanhada e registada. Para medir o efeito de fármacos foram 
feitos ensaios de crescimento/viabilidade celular (ensaio à base de resazurina e ensaio de 
sulforodamina B) tanto nas células parentais como nas selecionadas. Realizou-se, ainda, 
qRT-PCR e Western blot para averiguar a existência de possíveis mecanismos de 
resistência nas células selecionadas. Utilizou-se citometria de fluxo e qRT-PCR para 
procurar marcadores de estaminalidade (como, ABCG2 e Sox2) e o ensaio de formação de 
colónias para verificar o enriquecimento de CECs após uma exposição prolongada aos 
fármacos.  
A exposição aos fármacos levou a uma alteração temporária da morfologia celular, 
onde as células apareceram com uma estrutura do tipo mesenquimal. A exposição à 
cisplatina conduziu a um aumento na capacidade das células NCI-H460 resistirem tanto ao 
agente de seleção como à gencitabina e à doxorrubicina, contudo o mesmo não se verificou 
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em relação ao 5-FU. Após o tratamento com cisplatina, registou-se um aumento das 
proteínas anti-apoptóticas, Bcl-XL e XIAP, e da glicoproteína-P, em comparação com as 
células NCI-H460 parentais. Houve um ligeiro aumento na percentagem de células a 
expressar ABCG2 e, com menor intensidade, CD133. Relativamente à expressão génica do 
Bmi-1 e do Sox2, não foi registado nenhum aumento de expressão após o contacto com 
cisplatina. As células resistentes não demonstraram mais capacidade para formar colónias 
que as células parentais.  
Possivelmente, o aumento da resistência das células após o tratamento com 
cisplatina deve-se ao aumento de expressão das proteínas Bcl-XL, XIAP e glicoproteína-P. 
Como trabalho futuro ir-se-á silenciar estas proteínas através de iRNAs, numa tentativa de 
sensibilizar as células resistentes e validar, assim, estas moléculas como possíveis alvos 
terapêuticos para ultrapassar a resistência das células pulmonares cancerígenas à 
quimioterapia. 
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Abstract 
Tumour drug resistance is a major issue in the management of lung cancer, the 
worldwide leading cause of cancer-related deaths. It is currently believed that a small sub-
population of tumour cells, the cancer stem cells (CSCs) that possess self-renewal capacity 
and are able to sustain tumour growth, are partially responsible for tumour drug resistance. 
Indeed lung CSCs isolated from patients’ tumours have been shown to be particularly 
chemoresistant. Although the mechanisms underlying this resistance are not fully 
understood, over-expression of efflux pumps, over-expression of anti-apoptotic proteins 
and efficient DNA repair seem to be involved in resistance of CSCs to chemotherapeutic 
agents.  
In this project we aim to isolate and characterize putative lung CSC populations 
taking into account the chemoresistance mechanisms of these cells and to identify potential 
therapeutic targets to render them more sensitive to the chemotherapeutic drugs used in the 
clinic.  
Lung cancer cells (NCI-H460, A549) were incubated with the drugs cisplatin or 
doxorubicin, for three weeks followed by a drug-free recovery period, in order to isolate a 
putative CSC enriched population. Cell morphology was monitored and recorded 
throughout the experiment. Drug-selected and parental cells were incubated with 
chemotherapeutic agents and multiwell based cell growth/viability assays (resazurin-based 
and SRB assays) were performed. Western Blot and qRT-PCR were performed to identify 
possible chemoresistance mechanisms present in the putative CSC enriched populations. 
Flow cytometry analysis and qRT-PCR for stem cell markers (e.g.  ABCG2 and Sox2) and 
colony-forming assay were performed in order to assess enrichment of putative CSCs upon 
prolonged drug exposure.  
Drug treatment led to a transient alteration in cell morphology in both cell lines, 
whereby cells acquired a more mesenchymal-like structure. In NCI-H460 cells, cisplatin 
exposure led to increased resistance towards the selecting drug but also to doxorubicin and 
gemcitabine, although not for 5-FU. Increased expression of the apoptosis-related proteins 
Bcl-XL and XIAP and of the drug efflux pump P-glycoprotein was verified in the 
cisplatin-selected population, when compared to the parental NCI-H460 cell line. There 
was an apparent increase in the percentage of cells expressing the putative stem cell marker 
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ABCG2, and to a much lesser extent CD133, upon drug treatment. Bmi-1 and Sox2 gene 
expression do not appeared to be up-regulated in selected cells and colony-forming assay 
did not show any differences between NCI-H460 parental and resistant cells.  
The verified increased drug resistance after cisplatin treatment is possibly due to 
overexpression of Bcl-XL, XIAP and P-glycoprotein. We will now perform RNAi 
approaches to inhibit the combined expression of these proteins, in an attempt to 
chemosensitize resistant cells and to validate these molecules as therapeutic targets for 
overcoming chemoresistance in lung cancer cells. 
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1. Introduction 
 Over the last decades, our understanding of human cancer development has greatly 
increased and much progress has been made regarding cancer therapy. Nevertheless, our 
ability to develop clinically effective therapies based on this knowledge has had limited 
success [1]. After an apparently successful initial therapy, many tumours often relapse in a 
more aggressive form than the original tumour [2]. It has been postulated that a small 
subpopulation of cells with self-renewing capacity, multipotent differentiation [3-6], 
tumourigenic potential [3, 5, 7], expression of stem cell markers [3-12], increased 
invasiveness [6, 7], radioresistance [3], chemoresistance [3-7], and resistance to apoptosis 
[2, 11] could sustain malignant growth, the cancer stem cells (CSCs) [13]. In order to 
totally eradicate the tumour, cancer therapies should target this specific population of cells 
[2]. Studies regarding this population of cells have emerged after John Dick’s group 
demonstrated, in 1997, that acute myeloid leukaemia (AML) can contain a small 
population of cells that are capable to develop AML in immunodeficient mice after 
isolation and transference of these cells into the hosts [14]. The resulting leukaemia 
recapitulated the morphologic and immunophenotypic heterogeneity of the original disease 
[14].  
 In 2003, Michael Clarke’s group was the first to isolate CSCs from a solid tumour. 
They isolated CSCs from breast cancer and only the cells sorted through CD44
+
/CD24
low
 
phenotype were capable of transplanting disease into immunodeficient mice. This 
population, comprising about 11-35% of the cells constituting the tumour, gave rise to 
tumours in the mice that recapitulated the morphological and immunophenotypical features 
of the original tumour [15].  
  
1.1 Cancer Stem Cell hypothesis 
 Cancer stem cells are also known as cancer initiating cells because of their capacity 
to re-establish part of the phenotype found in the primary tumour when transplanted into 
animal models [16]. The cancer stem cell hypothesis states that cancer stem cells have 
three defining features: they are able to self-renew, to generate all the heterogeneous cell 
types present in a tumour, and are the only cells within a tumour that can give rise to 
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secondary tumours [17]. The features of CSCs  and their ability to resist conventional 
chemo and radiotherapy urge the need to find a specific therapy capable of destroying this 
subpopulation of cells [18]. CSCs have additional characteristic traits like a distinct surface 
marker expression profile, and the capacity of asymmetric/ symmetric cell division that 
allows the CSC population to maintain/expand itself and, at the same time, to give rise to a 
more differentiated progeny of tumour cells [17].  
 
1.1.1. Niche and origin of cancer stem cells 
 Stem cells have a specialized microenvironment that surround them, such as nerves, 
mesenchymal cells and extracellular matrix, which regulate how these cells participate in 
tissue regeneration, maintenance and repair [19, 20]. The niche interacts with them and 
release factors to regulate stem cell self-renewal and differentiation, confining the normal 
stem cells expansion. CSCs are, possibly, originated from a normal stem cell that mutated 
and escaped the normal niche, and then expands and aberrantly differentiates into the cells 
that would comprise the bulk of the tumour [21, 22]. When CSCs are out of the niche 
control they can use mechanisms that enable them to commander alternative niches in 
order to benefit of self-renewal signals [2]. If aberrant niche microenvironments are 
responsible for the modulation of CSCs, this could be a good target for cancer therapy [2].  
 It is not clear if CSCs originate from normal stem cells or from differentiated cells 
[23]. For many types of leukaemia there are evidence which favours a stem cell origin for 
CSCs [24]. In solid tumours, the data suggests that CSCs can originate from a stem cell, 
but it has been also postulated that they can have an origin in cells that are already in the 
differentiation process [25]. In 2008, Rapp et al. have induced plasticity in differentiated 
cells by injecting a cocktail of oncogenes in the host, reprogramming a series of events. 
After this, they proposed a model of oncogene-induced plasticity for CSCs origin [1]. Li et 
al, in 2009, defended that CSCs originate from normal stem cells (NSCs) due to genomic 
instability, and they suggest that CSCs are possibly responsible for the heterogeneity found 
in tumours [26]. 
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1.1.2. The hierarchy model and cancer stem cells  
 For more than a century, it has been acknowledged that tumours are composed of 
morphologically heterogeneous cells, and by the mid-twentieth century researchers 
understood that cancer cells also show functional heterogeneity both in vitro [27, 28] and 
in vivo [29, 30]. It has been documented that the vascular network around the tumour can, 
partially, dictate the phenotypic and behavioural heterogeneity found in tumour cells [31]. 
This includes non-cancer cells such as inflammatory cells, cancer associated fibroblasts 
and immature myeloid cells, all of them influencing tumour behaviour and often 
facilitating invasion and metastasis [32, 33]. The classical view of tumour formation is 
based on the “stochastic” or “clonal evolution” model [13], where the neoplasm, which 
results from one single cell, is seen as a mass of highly proliferative cells with similar 
potential for driving tumour growth. Tumour heterogeneity and progression are caused by 
microenvironment variations and genetic mutations in individual cells, followed by 
selection of mutant clones (clonal evolution) that are best adapted to support the further 
growth of the tumour [34]. An alternative concept that has been gaining increasing 
experimental support is the “hierarchy” or “cancer stem cell” model [35]. The cells within 
a tumour have heterogeneity and only a subpopulation of cells has the ability to initiate and 
perpetuate tumour growth. This model reports that cancer stem cells have stem cell-like 
properties, such as self-renewal and capacity to differentiate into the distinct cellular 
subtypes of the tumour (Figure 1.1). The heterogeneity found in the tumour is the result of 
the differentiation process from a stem cell precursor that sits on top of the tumour’s 
“differentiation hierarchy” [36], which may also include some level of plasticity. 
 The CSC theory model tries to explain both the wide heterogeneity observed in the 
original neoplasm and tumour relapse after treatment, proposing that a sub-population of 
cells is especially resistant to therapy [37]. However, the identification, quantification and 
clinical relevance of cancer stem cells are still controversial issues. It has been difficult to 
associate the development of some types of cancer to this theory, including the origin of 
cancer stem cells in the tumour [38].  
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Figure  1.1 - Two models for tumour heterogeneity and propagation. a | A normal cellular hierarchy, stem 
cells (at the apex) progressively generate common and more restricted progenitor cells, ultimately yielding all 
the mature cell types that constitute a particular tissue. b | In the clonal evolution model all undifferentiated 
cells have similar tumourigenic capacity. c | In the cancer stem cell (CSC) model, only the CSC can generate 
a tumour, based on its self-renewal properties and proliferative potential. d | Both models of tumour 
maintenance may underlie tumourigenesis. Initially, tumour growth will be driven by a specific CSC (CSC1). 
With tumour progression, another distinct CSC (CSC2) may arise due to clonal evolution of CSC1. This may 
result from the acquisition of an additional mutation or epigenetic modification. This more aggressive CSC2 
becomes dominant and drives tumour formation [35]. 
 
1.1.3. Properties and regulation of CSCs 
 Different properties of CSCs, such as self-renew potential [3-5], multipotent 
differentiation [3-6], tumourigenic potential [3, 5, 7], expression of stem cell markers [3-
12], increased invasiveness [6, 7], proliferation as tumour spheres [3-5], radio-resistance 
[3], chemo-resistance [3-7], quiescence [2], resistance to hypoxia [39-41] and resistance to 
apoptosis [2, 11] have been documented. The self-renewal potential allows the cells to go 
through unlimited cycles of cell divisions, giving origin to a wide range of 
differentiated/specialized cells, while maintaining the undifferentiated state [2]. These 
characteristics are responsible for the tumourigenic ability and heterogeneous phenotype 
found in tumours, being considered the key properties of CSCs [2]. CSCs express some 
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stem cell markers like CD133, a 5-transmembrane glycoprotein which function is still 
unknown, or ATP-binding cassette (ABC) transporter proteins, which are believed to be 
associated with therapy-resistant phenotype, making these surface markers a good target to 
find and isolate CSCs [12].  
According to the hierarchy model, CSCs are required for the initiation and growth 
of primary tumours. These capacities make them a possible cause for tumour relapse and 
metastasis [42]. Metastasis consist of a series of sequential transforming events involving 
invasion of tumour cells from primary neoplasms, followed by their dissemination through 
lymphatic or blood vessels, culminating in the establishment of metastasis at distant sites 
[37]. Recent data have supported the concept of metastatic CSCs, whereby a subpopulation 
of colorectal CSCs was found to possess exclusive metastatic potential and appeared to be 
the cause of distant metastasis in colon cancer patients. In addition, they exhibited 
enhanced chemoresistance [43]. It is possible that a tumourigenic CSC can acquire a 
migrating phenotype during an epithelial to mesenchymal transition process (EMT), 
whereby epithelial cells acquire mesenchymal features, occurring in the primary tumour 
[37]. This process would then allow these CSCs to spread to distant sites due to the loss of 
cell-cell and cell-extracellular matrix adhesion mediated by E-cadherin repression. A 
similar phenotype has been found between CSCs and cells which have undergone EMT in 
mammary carcinoma CSCs [44]. EMT is associated to tumour cell invasion and metastasis, 
and the process initiates with cell to cell adhesion disintegration and, consequently, loss of 
epithelial markers (such as E-cadherin) and gain of mesenchymal markers (such as 
vimentin). Subsequently, there is loss of basoapical polarization and the acquisition of 
front-rear polarization. Then, the cytoskeleton undergoes remodelling, with changes in 
cortical actin and actin stress fibres. Finally, cell-matrix adhesion is changed, with 
activation of proteolytic enzymes such as matrix metalloproteases [45]. These multiple 
steps result in detachment of cells from primary tumour, invasion of the surrounding 
stroma, which allows them to enter into circulation and reach new metastatic sites (Figure 
1.2) [46].   
 
6 
 
 
Figure  1.2 – CSCs and EMT process. Cancer cells undergoing EMT in primary tumour invade into tumour 
stroma and enter the circulation, allowing transport to distant organs. At metastatic sites, the cancer cells 
generate the new metastatic focus through MET (mesenchymal-epithelial transition) [46]. 
 
 
 To better understand the characteristics of CSCs it is essential to study their 
regulation, being reported that signalling pathways involved in self-renewal and 
differentiation reveal substantial overlaps between CSCs and normal stem cells [42]. The 
Notch pathway is involved in the stem cell maintenance and differentiation and has been 
implicated in CSC function. This pathway is activated by the binding of transmembrane 
ligands (Delta/Delta like proteins or Jagged) to the membrane receptor Notch. This induces 
the proteolytic cleavage of Notch by γ-secretase, promoting the release of Notch 
intracellular domain (NICD), which enters the cell nucleus and modifies gene transcription 
(Figure 1.3) [42]. It has been documented that Notch receptors and ligands are 
overexpressed in breast cancer, leading to transformation of normal breast epithelial cells 
into more resistant cells towards drug-induced apoptosis [47]. The Notch pathway has been 
correlated with CSCs. The activation of Notch signalling in glioma cells increases the 
expression of stem cell markers and enhances self-renewal [48, 49].  
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 The Wnt signalling is crucial for the control of multi/pluripotency, proliferation and 
differentiation in embryonic and adult stem cells and it is stated has necessary for CSC 
self-renewal and tumourigenicity [42]. This pathway is initiated when Wnt ligands link to 
transmembrane complex of receptors, the Frizzled (FZ) and lipoprotein receptor-related 
protein (LRP). A series of signalling steps are then activated, leading to stabilization of β-
catenin, which can modify gene expression (Figure 1.3) [42]. Malanchi et al proved that in 
skin CSCs the activation of β-catenin is enhanced, and when they removed the β-catenin 
gene in mouse skin cancer models a loss of CSCs was evident leading to complete tumour 
regression [50].  
Another signalling pathway playing a key role in regulation of stem cells of various 
tissues and in CSCs is the Hedgehog pathway [42]. Usually the receptor Patched (PTCH) 
inhibits Smoothened (a G protein coupled receptor), but when Hedgehog ligands bind to 
Patched receptor, the inhibition of Smoothened (SMO) protein is removed, which leads to 
the activation and translocation of Gli (glioma-associated oncogene homologue) 
transcription factor into the nucleus, providing transcription of its target genes (Figure 1.3) 
[42]. When this pathway is inhibited it is possible to suppress CSC proliferation and self-
renewal and enhance apoptosis [51]. Since these pathways seem to be related with CSC 
self-renewal and maintenance of stem cell phenotype, they are a promising approach to 
therapy [31].  
 
 
 
8 
 
 
Figure  1.3 - Principal pathways regulating CSCs. The Notch pathway (orange) allows the NICD to 
translocate to the nucleus and activates transcription. Different growth factors (e.g., EGF, FGF) can activate 
receptor tyrosine kinases (RTKs, green) that subsequently promote the activity of phosphatidylinositol-3-
kinase (PI3K), Akt and mammalian target of rapamycin (mTOR), among others, leading to enhanced protein 
translation, cell growth, and proliferation. Activation of Hedgehog (Hh, cyan) pathway promotes the 
translocation Gli into the nucleus and transcription of target genes. The Wnt pathway (yellow) leads to 
stabilization of β-catenin, which can proceed to activate gene expression. Specific factors in the CSC niches 
also play critical roles in regulating CSC self-renewal and differentiation, NO produced by endothelial nitric 
oxide synthase (eNOS, red) can stimulate the production of cyclic guanosine monophosphate (cGMP) and 
activate protein kinase G (PKG), resulting in enhanced Notch signaling. Low oxygen tension in the hypoxic 
CSC niche suppresses the activity of prolyl hydroxylase domain-containing proteins (PHDs, blue), leading to 
stabilization of hypoxia-inducible factors (HIFs) and the transcription of HIF target genes [42]. 
 
1.2. Isolation/Enrichment of CSCs  
 All the studies regarding CSCs are dependent upon the successful isolation of this 
population of cells, making this a pivotal step in determining the molecular pathways 
involved in the regulation of CSCs’ biological behaviour, such as tumour initiating 
potential, recurrence, therapy-resistance and metastasis [18, 23]. If it were possible to 
efficiently isolate the CSC population from each tumour, we could study the nature of their 
features when compared to non-CSCs. We would then be able to understand the 
mechanisms underlying therapy resistance of these cells to conventional therapy and find a 
way to sensitize them, avoiding tumour relapse [18].  
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1.2.1. Isolation of CSCs by using cell surface markers 
   The most frequent method to isolate the CSC population from a patient’s tumour 
is based on performing fluorescence activated cell sorting (FACS) for specific cell surface 
markers found in normal stem cells, such as CD44, CD133, CD24, CD34 or ABC 
transporter proteins [23, 42]. In most cases these markers are not specific to CSCs, e.g., 
CD133 was previously found in immature progenitor cells in normal haematopoietic, 
neural, endothelial and epithelial tissues [52-54]. Even so, these markers are used because 
they provide enrichment in CSCs and it is possible to isolate a more tumourigenic 
population than the rest of the tumour cells [42]. Indeed, CSC markers and gene signatures 
are associated with cancer progression and clinical outcome, and tumours enriched with 
CSCs have been shown to be more aggressive [55].  
Several stem cell markers for the isolation and identification of CSCs have been 
described in the literature. CD34 is used as a marker for CSCs in a wide types of 
leukaemias, such as, acute lymphoblastic leukaemia (ALL) [56] and AML [14, 16, 57] 
(Table 1.1). In solid tumours, the most reported markers for the isolation of CSCs are 
CD44 and CD133. CD44 has been used to identify CSCs in breast cancer [15], in head and 
neck squamous cell carcinoma (HNSCC) [58], in prostate cancer [59] and in pancreatic 
cancer [60]. The CD133 marker is the most frequently used marker  to isolate CSCs in a 
wide spectrum of solid tumours and, unlike other markers that are usually used in 
combination, CD133 is most of the times used on its own (Table 1.1) [23]. CD133 has 
been used as a marker for CSCs in medullo-blastoma [61], glioblastoma [58],  colon cancer 
[62-64], pancreatic cancer [65], non-small cell lung cancer  [8] and others [23]. 
 By labelling tumour cells with fluorescent antibodies for stem cell markers, it is 
possible to isolate the positive cells (those who express the marker, the population of cells 
thought to be the CSCs)  and  the negative ones (non-CSCs) from the same tumour, using 
FACS [18]. This approach allows the separation of distinct populations of cells that can be 
used to study tumour features, such as tumourigenicity, chemo/radio resistance, gene 
expression and others [11]. Eramo et al. identified a rare population of CD133
+
 cells in 
lung cancer and a low number of these cells were able to reproduce the original tumour 
when transplanted into an immunocompromised mice, while the CD133
-
 population did 
not present tumour-initiating activity [4]. Bao et al. demonstrated that CD133
+
 cells in 
fresh glioblastoma specimens or glioma xenografts irradiated in vivo were more resistant to 
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ionizing irradiation than CD133
-
 cells [66]. They observed that in this model, CD133
+
 cells 
activated the DNA damage checkpoint response more efficiently than CD133
-
 cells [66]. 
Tumour xenografts derived from CD133
+
 and CD133
-
 cells of pancreatic carcinoma were 
treated with gemcitabine (a drug commonly used in pancreatic cancer therapy) and the 
results revealed that CD133
+
 population was more resistant than the negative population. 
Additionally, immunohistochemistry analysis revealed that the tumour xenografts derived 
from CD133
+
 cells reproduced the primary tumour at histological level [65].  
 It is important to note that the frequency of cells expressing a specific marker may 
vary within the same tumour type (Table 1.1). In colon cancer, CD133 does not identify 
CSCs in all patient samples, suggesting that tumours arising from the same tissue may 
express different surface markers e.g., CD44 and CD133 are co-expressed in colon cancer, 
but they identify different populations of cells [23]. Some researchers use a combination of 
markers in order to obtain a more purified population of CSCs, like Chen and colleagues 
who used CD133
+
CD44
+
 cells to enrich a population of stem-like cells in a colon cancer 
cell line (HCT116) [67].   
1.2.2. Functional assays for CSC isolation 
 Due to the variation of CSC surface phenotypes in tumours of the same type, some 
groups tried to isolate CSCs based on their functional activity.  
High aldehyde dehydrogenase (ALDH) activity has been described in murine and 
human hematopoietic, neural stem and progenitor cells [68-70]. Some investigators have 
used ALDH to isolate CSCs and found these cells in AML [71, 72], in primary breast [73] 
and colon cancer [74]. 
  Another method to isolate CSCs by FACS is based on their capacity to efflux the 
fluorescence dye Hoechst 33342, which is due to overexpression of ABC transporter 
proteins such as ATP-binding cassette sub-family G member 2 (ABCG2) [75]. The cells 
that have this ability are called side population (SP) and show self-renewal activity, 
differentiated progeny production, tumourigenicity, expression of CSC markers and stem 
cell genes [76]. SP have a high capacity of resistance to chemotherapeutic agents and are 
crucial in tumour recurrence [76-78]. Considering these features are mainly attributed to 
ABCG2 and its expression is conserved in stem cells, it was consider as a novel biomarker 
of CSCs [75]. Although there are many markers that can be used to isolate CSCs, the 
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FACS methodology is not always the best approach, due to the low and variable marker 
expression. The isolated population is not always totally pure and/or the marker expression 
rapidly equals that of the tumour, before isolation [11]. 
 
Table  1.1 - Markers used in isolation and identification of CSC from different cancers. Adapted from [35, 
42]. 
EpCAM: epithelial cell adhesion molecule; SP: Side Population. 
Cancer type CSC markers % of CSC cells in 
tumour 
Acute lymphoblastic leukaemia 
(ALL) 
CD34
+
CD10
-
 / CD34
+
CD19
-
 8 ± 4 / 3 ± 1 
Acute myeloid leukaemia 
(AML) 
CD34
++
CD38
-
 0.02 - 2.00 
Breast CD44+CD24low 
CD44
+
CD24
-
ALDH1
+
 
Thy-1
+
CD24
+
CD45
-
 
11 - 35 
0.1 - 1.2 
1,0 – 4,0 Head and neck 44 0.1 – 41.7 
Prostate CD44
+α2β1
high
CD133
+
 0.1 – 0.3 
Pancreas CD44
+
CD24
+
EpCAM
+
 0.2 – 0.8 
Colon CD133 
EpCAM
high
CD44
+
 
ALDH1 
1.8 – 24.5 
0.03 – 38.0 
3,5 ± 1,0 Lung CD133
+
 0.3 – 22.0 
Liver CD90
+
CD45
-
 0.7 – 6.2 
Brain CD133 
SP 
19 - 29 
0.15 – 1.2 
Ovarian CD44
+
CD117
+
 
CD133
+
 
0.1 – 0.2 
0.3 – 35.0 
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1.2.3. CSC enrichment using in vitro assays 
 There are some alternative strategies to enrich a CSC population, using in vitro 
assays, which enable at the same time the discovery and the study of CSCs capacities. 
When a tumour is formed, the rapid expansion of cancer cells creates a hypoxic 
microenvironment followed by periods of re-oxygenation that allows tumour propagation. 
It has been postulated that hypoxia can lead to the development of more aggressive cancer 
by selecting the most resistant population, the one that could survive to adverse conditions 
like lack of oxygen and nutrients [39-41]. Some authors have explored environment 
changes that can lead to more aggressive tumours, e.g., Louie et al. could enrich a CSC 
population with stem like properties and metastatic potential by exposing a human 
metastatic breast cancer cell line to cycles of hypoxia followed by re-oxygenation [79].  
 The non-adherent sphere and the colony-forming assays are based on the growth of 
cells from a stem or progenitor cell. However the cell culture conditions used are different. 
In the first method, cells are in a non-adherent condition and serum free media containing 
growth factors (e.g. EGF-epidermal growth factor and FGF2-fibroblast growth factor 2). In 
the second one, cells grow on a substitute of the basal membrane (e.g. matrigel) with 
appropriated media. In these in vitro assays, cells are in adverse environments, are 
separated from each other (and in the first assay mentioned they are also in non-adherent 
conditions); only a cell possessing stem properties will be able to survive and generate a 
tumour sphere/colony by itself [31, 35]. The non-adherent assay also forces the cells to 
grow in 3D structures and when the spheres are too big a real tumour could be partially 
simulated, making this assay a useful surrogate for the in vivo CSC assay [31]. 
 All the approaches described above to isolate (such as FACS) or to enrich (like 
non-adherent sphere and the colony-forming assays) CSC populations usually require 
confirmation with an in vivo assay (or when this is not possible an in vitro assay) that they 
are indeed of CSCs. The gold-standard assay to evaluate the presence of CSCs is 
xenotransplantation, when a selected number of the tumour cells are injected, preferably in 
an orthotopic location, in immunocompromised mice [35]. With this assay it is possible to 
check the self-renewal and tumourigenic potential of the cells tested, verifying if they are 
capable to recapitulate the cellular composition of the primary tumour. [31]. Eramo et al. 
could produce a tumour xenograft by injecting 10
4 
undifferentiated lung cancer cells in 
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severe combined immunodeficiency (SCID) mice, although 5x10
4
 differentiated cells 
injected were unable to generate tumours in the same tested mice [4].  
 
1.3. Mechanisms of CSC resistance to chemo- and radiotherapy and 
CSC-targeted therapies 
 Current cancer therapy has not been sufficient to successfully eradicate tumour 
cells. Considering that it is now believed that many cancers could be driven by a 
subpopulation of cells with capacity to sustain tumour growth, the CSCs, a CSC-targeted 
therapy seems to be the best option to totally eradicate the tumour. In order to achieve this, 
it is imperative to understand the mechanisms behind CSC therapy resistance. It was 
suggested that CSCs have gained genetic and cellular adaptations capable of making them 
more resistant to therapy [80]. Many studies have been performed after an efficient 
isolation of CSCs in different tumours to try to explain and understand why these cells are 
chemo- and radioresistant. Although the mechanisms underlying this resistance are not 
fully understood, relative dormancy/slow cell cycle kinetics, efficient DNA repair, high 
expression of multidrug-resistance membrane transporters and resistance to apoptosis seem 
to be the mechanisms involved in CSC resistance to therapy (Figure 1.4) [80].   
 
Figure  1.4 - Mechanisms leading to CSC resistance to chemo and radiotherapy. Cancer stem cells have 
been found to exhibit a number of genetic and cellular adaptations that confer resistance to classical 
therapeutic approaches, including relative dormancy/slow cell cycle kinetics, efficient DNA repair, high 
expression of multidrug-resistance-type membrane transporters, resistance to apoptosis, and protection by a 
hypoxic niche environment [80]. 
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 Conventional therapies appear to be capable of eliminating most of the cells in a 
tumour but not CSCs, which are less sensitive to chemotherapeutic drugs and have higher 
proliferation potential [13]. Thus, the neoplasm could initially shrink  during the first 
rounds of therapy but, in time, CSCs would be able to re-establish the original tumour 
(Figure 1.5) [13]. By contrast, if clinical therapies were targeted against CSCs, the 
neoplasm reduction would be softer, but the cells would not be able to sustain tumour 
growth, leading to its degeneration (Figure 1.5) [13]. Generally it is believed that a high 
proportion of CSCs in a tumour are correlated with poor prognosis, e.g. high ALDH 
expression is assumed to be associated with poor prognosis in various tumour types, such 
as breast cancer [73], AML [71], prostate [81], head and neck squamous cell carcinoma 
[82] and early-stage lung cancer [6]. It is also believed that radiation and chemotherapy 
often serve to enrich the resistant CSC population and possibly promote more resistant 
clones within a heterogeneous CSC population, e.g. evidence of radiation-induced 
enrichment has been found in brain [83] and breast [84] CSCs. This feature has been 
utilized as a method to enrich the CSC population, as seen with gemcitabine treatment of 
pancreatic cancer [85], cyclophosphamide treatment of colorectal cancer [74] and with 
cisplatin, doxorubicin and methotrexate treatment of lung cancer [5]. This may indicate 
that only a specific and targeted therapy for CSC population would be a successful 
approach in fighting cancer [31]. It is now established that combination therapy helps 
preventing the development of cancer resistance. However the co-administration of 
chemo/radio therapy is not effective in all types of cancer and, in most cases, is much too 
toxic to be tolerated by the patient [80]. It would be important to test if CSC-targeted 
therapies combined with traditional cancer therapies is an appropriate strategy for fighting 
cancer [80]. 
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Figure  1.5 - Comparison of conventional and CSC-based anticancer therapies. A) Conventional therapies 
(brown flash) target the tumour bulk but are inefficient against CSCs (red), which can subsequently re-
establish the original tumour. B) CSC-based anticancer therapies are expected to eliminate CSCs. One 
approach is either direct killing of CSCs or their differentiation into non-CSCs (orange flashes) that can be 
targeted in combination with standard treatments. Another strategy entails the disruption of CSC niches, such 
as hypoxic regions or perivascular regions, or niche-derived signals (blue flashes), which are required for 
CSC maintenance. Both approaches are additionally combined with conventional anticancer agents (brown 
flash) to destroy bulk tumour cells. Blood vessels are depicted in pink [42]. 
 
 Radiotherapy and most type of chemotherapeutic agents act by disrupting the 
cancer cell DNA integrity and it is possible that CSC resistance is due to increased 
expression of DNA integrity-maintenance systems [86]. Normal stem cells have efficient 
DNA mutation defence systems but, if these cells mutate, can give rise to CSCs and then it 
is possible to find in CSCs high DNA damage repair potential [80]. Numerous experiments 
have demonstrated chemo/radio resistance in CSCs, e.g. when a tumour was a target of 
radiation all the cells showed equal levels of damage, but CSCs had the ability to 
recuperate quicker [83]. In pancreatic cancer, cell cycle analyses after gemcitabine 
treatment showed that CD133
+
 cells stopped proliferating but did not undergo apoptosis. 
When gemcitabine was withdrawn, these cells immediately started to recapitulate the 
cancer cell pool. In contrast, the CD133
-
 cells (the more differentiated cells, representing 
the majority of tumour cells) became apoptotic after gemcitabine treatment [37]. The 
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family of checkpoint kinase 1/2 (Chk 1/2 Kinase) is one potential modulator of CSC 
resistance to DNA-targeting agents, by arresting the cell cycle to allow DNA repair [66]. 
These Kinases have higher basal and inducible activities in CSCs than non-CSCs [66] and 
Chk 1/2 inhibitors can partially reverse the resistance of glioblastoma CSCs to radiation 
[66]. 
Radiotherapy depends on the production of oxygen free radicals to cause damage to 
DNA. It has been postulated that areas of low oxygen levels within a tumour create a 
microenvironment capable of partially protecting cells against radiotherapy-induced 
damage [87]. Another way to protect cells from radiotherapy is the presence of free radical 
scavengers. Vlashi et al. found this characteristic enhanced in breast CSCs [88]. It has also 
been found that CSCs are enriched around blood vessels, depending on signals derived 
from them [42]. This may explain why antiangiogenic therapies (targeting CSC niche) 
seem to have a good efficacy [80]. Theoretically, the antiangiogenic therapies may provide 
a hypoxic microenvironment, conferring radioresistance in cells, although the clinical 
relevance of this is still unknown. It is possible to speculate that radiation treatment may be 
more effective in cancer treatment before any antiangiogenic chemotherapy is applied [80].  
 Stem cells can also protect DNA integrity by preventing the action of mutagen 
chemicals in cellular DNA. This is possible due to high expression of efflux transporters 
from ABC gene family, that allows cells to preserve their genome more efficiently [89]. 
These drug efflux pumps were found in CSCs and they seem to be partially responsible for 
the chemotherapy resistance phenotype, since they are able to  transport the drug out of the 
cell [90]. When CSCs can be separated from non-CSCs in the same cell line by their 
capacity to efflux the Hoechst 33342 fluorescent dye (due to the presence of ABC 
transporters) they are called side-population (SP) [75]. When tests of resistance to 
chemotherapeutic drugs were made, the SP cells showed higher percentage of cell viability 
than non-SP cells after 24 hours of drug exposure [7]. Although this mechanism of cell 
defence does not explain radiation resistance, a blockage of multidrug efflux pumps may 
provide an efficient method to make cells sensitive to clinical chemotherapeutic drugs 
already used [80].      
 Many authors have utilized Western blot assay to evaluate the protein levels of 
specific pathways, to find a possible cause for tumour-resistance therapy. The 
overexpression of apoptosis inhibitor proteins may also be behind of CSCs resistance to 
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therapy. The mitochondrial pathway of apoptosis is triggered by cytochrome c release and 
Smac (second mitochondria-derived activator of caspase) activation [91]. When Smac is 
associated with direct inhibitor of apoptosis binding protein (Smac/DIABLO) they promote 
apoptosis by neutralizing the inhibitor of apoptosis (IAP) [91]. Various human cancers 
have high levels of IAPs, including the XIAP (X-linked inhibitor of apoptosis protein) 
isoform, which is implicated in poor treatment responses [92, 93]. Vellanki et al. could 
alleviate radioresistance of glioblastoma CSCs by promoting apoptosis using a XIAP 
inhibitor [84], proving that XIAP is implicated in radioresistance of glioblastoma CSCs 
and perhaps suggesting a new CSC-targeted therapy [80]. Another approach that can be 
used is acting on RNA translation process, by silencing such proteins [94].  
 Self-renewal, which drives tumourigenesis, and differentiation capacity seem to be 
key properties of CSCs [2]. Targeting the molecular pathways behind the control of 
multi/pluripotency, proliferation and differentiation represent an attractive goal for drug 
discovery since they may provide positive strategies to eradicate CSCs [80]. The Wnt 
pathway, plays an important role in differentiation of normal stem cells and its activation 
promotes genomic instability, leading to transformation/mutation of the cells [83], e.g. 
Shiras proposed that this pathway possibly promotes conversion of NSC into CSCs in 
gliomas [95]. Genomic instability is seen as a way for tumour cells to both survive and 
develop additional adaptive mutations [80]. To overcome this possibility, Wnt inhibitors 
have been designed to specifically target this pathway [96]. In other cases, the effect of the 
inhibitors may not always eliminate the CSCs directly, but rather promote their 
differentiation, meaning that they are no longer able to self-renew and to support tumour 
growth [42]. It was reported that differentiation of glioma CSCs sensitized them to therapy, 
impaired the secretion of angiogenic cytokines, inhibited motility and reduced the CSC 
tumourigenicity [97].  
Notch/γ-secretase/Jagged signalling pathway is defined as an important regulator of 
differentiation and helps to control cell fate [98]. It was found to be activated in breast 
cancer [99] and endothelial cells [100] in response to radiation. It was reported that 
inhibition of Notch signaling via γ-secretase inhibitors can potentially block CSC self-
renewal, decrease tumour growth and prolong survival in medullo-blastoma and glioma 
[101, 102]. Significant efforts to downregulate Notch pathway are being studied, e.g. a γ-
secretase inhibitor is in clinical development for treating leukaemia [80]. The hedgehog 
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signalling, being involved in proliferation and self-renewal of stem cells, may also provide 
a good approach for drug discovery, e.g. inhibition of this pathway with an antagonist of 
the hedgehog co-receptor SMO, eliminated CSCs in chronic myeloid leukaemia [103]. In 
glioma, tumour growth was suppressed when the same antagonist was  co-administrated 
with a standard chemotherapeutic drug (temozolomide) [51]. 
 
1.4. Drug resistance in lung cancer 
 Lung cancer is the worldwide leading cause of cancer related deaths and one of the 
most intractable cancers [23]. In general, after an apparent good response to initial therapy, 
it has a particularly poor prognosis with five-year survival lower that 15% due to late 
presentation, disease relapse and low rate of curative therapy [8]. There are two main types 
of lung cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). 
The latter includes three major histological types: adenocarcinoma, squamous cell 
carcinoma (SCC) and large cell carcinoma. About 15% of lung tumours are SCLCs and 
arise in the larger airways, grow rapidly and have a neuroendocrine component. 
Adenocarcinoma represents about 40% of NSCLCs and usually originates in peripheral 
lung tissue. SCCs represent 25% of NSCLCs and commonly start near a central bronchus. 
Large cell carcinomas are believed to derive from neuroendocrine cells and may be 
observed in combination with other types of NSCLC [2]. Lung cancer has been object of 
intense studies because of its association to chemotherapeutic drug resistance and lung 
cancer cell lines are widely used for drug resistance experiments. NCI-H460 and A549 are 
examples of the most utilized cell lines in lung cancer studies. NCI-H460 cell line is 
tumourigenic and was derived in 1982 from the pleural fluid of a patient with large cell 
lung carcinoma by A.F. Gazdar and associates. The A549 cell line was initiated in 1972 by 
D.J. Giard, et al. after an explant culture of lung adenocarcinoma from a 58-year-old 
Caucasian male. All of this cell lines were isolated from NSCLC patients, present adherent 
growth properties and have an epithelial morphology [104]. Several studies have been 
published with these cell lines, e.g. Almeida et al reported that A549 cell line showed to be 
significantly more resistant to cisplatin than NCI-H460 cell line and studied how these cell 
lines responded to drug treatment [105].  
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 Drug resistance of malignant tumours is a very complex phenomenon, being the 
mechanisms behind chemoresistance probably acting in a combinatory way, making the 
understanding of resistance quite complicated. Apart from intrinsic resistance, the tumour 
cells can acquire resistance during chemotherapy treatment. The chemotherapeutic drugs, 
to be efficient, must reach the tumour cells through the blood vessels, however the 
vasculature of solid tumours is highly variable [106]. Such drugs usually act by disrupting 
the cell cycle process. Cisplatin, one of the most potent anticancer drugs is used in a wide 
range of tumour types. This drug interacts with DNA forming DNA adducts, activating 
signal transduction pathways that culminate in apoptosis [107]. Gemcitabine, another 
anticancer drug commonly used, is a cytidine analog. Following influx through the cell, 
gemcitabine undergoes complex intracellular conversion to the nucleotides gemcitabine 
diphosphate (dFdCDP) and triphosphate (dFdCTP) responsible for its cytotoxic actions. 
Incorporation of dFdCTP into DNA is most likely the major mechanism by which 
gemcitabine causes cell death. After this incorporation on the end of the elongating DNA 
strand, one more deoxynucleotide is added and thereafter, the DNA polymerases are 
unable to proceed and the cell will activate the apoptosis pathway [108]. Doxorubicin is an 
anticancer drug with a wide spectrum of activity, since it has the ability to intercalate the 
DNA helix and to bind proteins involved in DNA replication and transcription. Such 
interactions lead to inhibition of DNA, RNA and protein synthesis, resulting in cell death 
[109]. 5-Fluorouracil (5-FU) has played an important role in treatment of cancer and is 
usually administrated in combination therapy. It has been proposed to be incorporated into 
RNA and DNA, but the mechanism of action reported is the capacity to inhibit thymidylate 
synthase (TS). Inhibition of TS, a key enzyme of pyrimidine synthesis, will impair DNA 
replication and culminate in cell death [110]. The mechanisms underlying cancer drug 
resistance are normally associated with reduced drug uptake, increased drug inactivation, 
and increased DNA adduct repair [107]. 
 In 2007, Ho et al isolated the SP of cells from lung cancer cell lines and discovered 
that SP cells display significantly increased invasiveness, when compared to non-SP, using 
an in vitro Matrigel invasion assay. These cells were also more tumourigenic than non-SP 
cells in vivo, i.e. only a small number of SP cells were required to induce tumour formation 
upon injection into mice. This study also showed that SP cells are more resistant to drugs 
commonly used in chemotherapy. Several drugs were tested, such as cisplatin, gemcitabine 
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and doxorubicin, in different lung cancer cell lines  (e.g. NCI-H460 and A549) for 24 
hours and SP cells exhibited higher resistance to chemotherapeutic drugs than non-SP cells 
[7]. Eramo et al reported, using MTT assay, that lung cancer stem cells are resistant to 
chemotherapy after 5 days of drug exposure, and also that lung cancer spheres are 
tumourigenic in vivo and can reproduce the human tumour when injected in 
immunocompromised mice [8].  
 As mentioned above, there CSCs and EMT cells share many common features. 
Indeed, EMT is associated with resistance to multiple drugs and allows rapid tumour 
progression. Clarifying this correlation may help clinicians to select an optimal anticancer 
drug treatment [46]. The concept of EMT was first developed in the field of embryology, 
but has been recently extended to cancer progression and metastasis [111]. Cells 
undergoing EMT become invasive and develop resistance to anticancer agents. It was also 
reported that EMT can be induced by chemotherapeutic agents and by stress conditions, 
such as exposure to radiation and hypoxic conditions [112]. The biology of EMT has been 
clarified in tumour samples through EMT-associated markers, such as mesenchymal 
specific markers (e.g. vimentin and fibronectin) [113], epithelial specific markers (e.g. E-
cadherin and cytokeratin) [114] and transcription factors (e.g. Snail and Slug) [115].  
 Stable pancreatic cancer cell lines resistant to gemcitabine, due to continuous 
exposure to the drug, can undergo EMT with increased expression of Snail and Twist 
(EMT-regulatory transcription factors) [116]. On the other hand, EMT has been reported to 
confer resistance to chemotherapeutic drugs. Lung cancer cell lines that have undergone 
EMT (expressing vimentin and/or fibronectin) were insensitive to the growth inhibitory 
effect of EGFR (epidermal growth factor receptor) inhibition by erotinib both in vitro and 
in xenografts [117]. As EMT has been associated to resistance to multiple drugs and 
metastasis, clarifying such relation may help the development of optimal anticancer drug 
treatments [46]. Some molecular mechanisms seem to be involved with EMT in cancer 
progression. Diminished expression of E-cadherin can lead to tumour progression, 
metastasis and poor prognosis in various human carcinomas [114] and loss of the TGF-β 
signaling pathway results in the progression of cancer, once TGF-β is a strong growth 
inhibitor [118]. Some transcription factors, such as zinc finger proteins (ZEB1, ZEB 2), 
bH2H protein (twist) and the Snail family of zinc finger proteins (Snail, Slug) are known to 
repress E-cadherin, promoting EMT [119]. The involvement of small non-coding RNA 
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(microRNA) in the regulation of EMT-related genes as also been shown [120], for instance 
miR10b overexpression is associated with invasiveness and metastatic potential [121]. The 
correlation of these mechanisms with EMT may prove an important tool for future drug 
design [46]. 
   
1.5. Aims 
It is currently believed that putative cancer stem cells (CSCs) (a small sub-
population of tumour cells with self-renewing capacity that sustains tumour growth) are, in 
part, responsible for chemoresistance. CSCs seem to share some of the resistance 
mechanisms of NSCs. Although these mechanisms are not fully understood, over-
expression of efflux pumps, over-expression of anti-apoptotic proteins and efficient DNA 
repair seem to be involved in resistance of CSCs to chemotherapeutic agents. Despite 
many advances in the CSC field, many progresses are needed in order to better understand 
such regulation and possibly identify potential therapeutic targets to overcome 
chemoresistance in these cells.    
In this project we aim to isolate CSCs from lung cancer cell lines using FACS or by 
exposing cells to chemotherapeutic drugs. We then aim to study the resistance of the 
isolated populations against chemotherapeutic drugs used in the clinic (such as cisplatin, 
gemcitabine, 5-FU and doxorubicin). If we determine that the selected sub-populations of 
cells have increased chemoresistance, we aim to investigate the drug resistance 
mechanisms involved in order to identify potential therapeutic targets to overcome CSC 
resistance to the chemotherapeutic agents already used in the clinic.   
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2. Materials and Methods 
2.1. Chemicals and Reagents 
 All chemicals were purchased from Sigma-Aldrich, unless stated otherwise. All 
tissue culture materials and reagents were purchased from Becton Dickinson or TPP and 
Lonza, respectively, unless otherwise stated.  
 
2.2. Cell lines and culture conditions 
 Two human non-small cell lung cancer cell lines were used in this study: NCI-
H460 and A549. Cell lines were kindly provided by Doctor George Don Jones (University 
of Leicester, United Kingdom). NCI-H460 is a large cell lung carcinoma cell line and 
A549 is an adenocarcinoma cell line. Both cell lines are epithelial and have wild type P53. 
Cells were grown as a monolayer in Roswell Park Memorial Institute – 1640 medium 
(RPMI-1640) supplemented with 10% (v/v) heat –inactivated foetal bovine serum (FBS), 
in a humidified atmosphere at 37 
º
C and 5% CO2. Cells were passaged twice a week using 
TrypLE™ Express. 
 
2.3. Analysis of ABCG2 and CD133 expression by flow cytometry  
Expression levels of the cell surface membrane proteins ABCG2 and CD133 were 
assessed by flow cytometry. 
Single-cell suspensions were obtained using versene (Gibco) in order to protect the 
epitope recognized by the utilized antibodies, as initially obtained results using Tryple 
Express to detach cells showed that the protein was not being properly recognised by the 
ABCG2 antibody. Cell suspensions were washed twice with the labelling buffer, 
containing phosphate buffered saline (PBS), 0.2% ethylenediaminetetraacetic acid 
(EDTA), and 0.5% bovine serum albumin (BSA). Cells were then incubated with the 
specific antibodies: Bcrp1/ABCG2–phycoethrin (PE) antibody (R&D systems), CD133/1-
PE antibody and IgG-PE (both from Miltenyi Biotec), diluted 1:10 in the labelling buffer 
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and incubated for 10 minutes at 4 °C in the dark. Unbound antibody was removed by 
washing cells with labelling buffer. Cells were then resuspended in an appropriate volume 
of labelling buffer and, kept on ice in the dark until flow cytometry analysis. Flow 
cytometric data acquisition was performed at IBMC’s Advanced Flow Cytometry Unit 
using a FACS Calibur (Becton Dickinson). Acquired data, from a minimum of 30,000 
events per sample, were analysed using Flow-Jo software (version 7.6.5, Treestar, 
Ashland, OR) and Microsoft Office Excel 7.0 (Microsoft, Redmond, WA). 
 
2.4. Fluorescence activated cell sorting (FACS) 
 This approach allows the separation of distinct populations of cells that can be used 
to study tumour features, such as tumourigenicity, chemo/radio resistance, gene expression 
and others [11]. The tumour cells are labelled with fluorescent antibodies for stem cell 
markers and it is possible to isolate the positive cells (those expressing the marker, the 
population of cells thought to be the CSCs)  and  the negative ones (non-CSCs) from the 
same tumour, using fluorescence activated cell sorting (FACS) [18].  
 To perform cell sorting, 10
6
 cells were labelled with the specific Bcrp1/ABCG2-PE 
antibody as described above, except that cells were incubated with the antibody for 30 
minutes at 4 
o
C in the dark. The labelled cells were analysed and ABCG2
+
 and ABCG2
-
 
sub-populations separated using a FACSAria cell sorter (BD Biosciences). Cell sorting 
efficiency was assessed immediately after cell separation by determining the % of cells 
expressing ABCG2 in each of the cell sub-populations by flow cytometry. 
Upon cell sorting cells were plated in fresh RPMI-1640 medium supplemented with 
10% (v/v) FBS and 0.1 % of gentamicin and expanded for at least 7 days. 
 
2.5. Cell growth/viability assays  
 To investigate cell response towards chemotherapeutic agents (cisplatin, 
doxorubicin, gemcitabine and 5-FU), two different multiwell plate cell growth assays were 
performed:  a resazurin-based assay and the Sulforhodamine B (SRB) assay.   
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2.5.1. Resazurin-based assay (PrestoBlue): 
 PrestoBlue reagent (Life Technologies) is a resazurin-based solution that functions 
as a cell viability indicator by using the reducing power of living cells to quantitatively 
measure the proliferation of cells. The PrestoBlue reagent contains a cell-permeant 
compound that is blue in colour and virtually nonfluorescent.  When added to cells, the 
PrestoBlue reagent is modified by the reducing environment of the viable cell, turns red in 
color and becomes highly fluorescent.   
Cells were seeded in 96-well plates, left to adhere for 24 hours, and incubated with 
chemotherapeutic agents for 48 hours. At the end of the incubation period, the media was 
removed, cells were washed once with PBS, 50 μL of PrestoBlue  added to each well and 
incubated at 37 ºC for 45 minutes, in the dark. Fluorescence excitation and emission were 
measured at 560 and 590 nm, respectively using a multiwell plate reader (Synergy Mx, 
Biotek).  
2.5.2. SRB assay: 
 The SRB assay is a colorimetric assay that measures biomass. SRB is a pink dye 
that directly binds to basic amino acids of cells that have been previously fixed by 
trichloroacetic acid (TCA). The incorporated dye is then solubilised in a Tris-Base solution 
(under basic conditions) and colorimetric evaluation (optimal wavelength for measurement 
of the optical density of SRB is 564 nm) provides an estimate of protein mass which is 
directly proportional to cell number [122]. 
The SRB assay was always performed following cell incubation with PrestoBlue, 
allowing analysing the same cells by two different cell growth/viability assays. Upon 
performing the PrestoBlue assay, cells were fixed in cold TCA (Merck) to a final 
concentration of 10% (v/v) and incubated on ice for 1 hour. The TCA was then removed, 
the wells washed with distilled water and allowed to dry. 50 μL of 0.4% SRB (w/v, 
prepared in 1% acetic acid) were added to each well and incubated at room temperature for 
30 minutes. Afterwards, the SRB was removed, the wells were quickly washed three times 
with 1% acetic acid (v/v) (Merck), and allowed to air dry. The incorporated SRB dye was 
then solubilised by adding 100 μL of 10 mM Tris-Base solution, the plates were briefly 
shaken and the optical density (OD) of each well was measured spectrophotometrically in 
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a multiwell plate reader (Synergy Mx, Biotek) at a wavelength of 560 nm subtracting the 
background measurement at 655 nm. 
2.5.3. Optimization of the starting conditions for the resazurin-based and SRB assays 
 Sensitivity of the cell growth/viability assays was tested by determining the 
linearity between the number of cells per well and the OD at 560 nm for the NCI-H460 cell 
line after 24 hours in culture. Cells were seeded at different densities (from 250 to 16,000 
cells) in a 96-well plate (four replicate wells per cell density) and incubated for 24 hours 
prior to processing and fluorescence or absorbance reading as described above.  
 For determination of the optimal starting cell density, cells were plated in 96-well 
microplates at densities of 250 – 16,000 cells per well in quadruplicate. Cells were left to 
adhere for 24 hours and further incubated for 48 hours in a humidified chamber at 37 
º
C 
and 5% CO2. Cells were then processed for the PrestoBlue and SRB assays (as detailed 
above).  
2.5.4. Cell incubation with chemotherapeutic agents 
 Cells were seeded at a density of 2.0 x 10
3
 cells per well on 96-well microplates, 
left to adhere for 24 hours, and incubated with various concentrations of cisplatin (1 to 10 
µM), doxorubicin (0.01 to 0.5 μM), gemcitabine (10 to 50 nM) and 5-FU (5 μM to 20 μM) 
for 48 hours. In addition, cells were also processed at time zero (T0) of drug incubation, 
i.e. 24 hours following cell seeding, in order to determine % cell growth. Background 
control wells, containing the same volume of complete culture medium with or without 
chemotherapeutic drugs were included in each experiment and used to correct the reading 
changes due to external factors (not to cells). Cells incubated with drug-free complete 
medium were used as controls, representing 100% cell growth/viability. The % of cell 
growth (taking T0 into account) or % cell survival (not taking T0 into account) in the cells 
treated with chemotherapeutic agents was determined in comparison to the control cells 
and the population of cells with increased drug resistance will have higher percentage cell 
survival, which can be measured by using different assays that provide us with an indirect 
measure of cell number. Three replicate wells were used for each condition. Cell 
growth/survival was assessed by the PrestoBlue and SRB assays. Results are shown as the 
mean ± SD of three independent experiments, except when stated otherwise. GI50 
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(concentration of drug that inhibits cell growth in 50%) of tested populations was 
calculated using GraphPad Prism 5.04. 
 
2.6. Enrichment of putative CSCs upon treatment with chemotherapeutic 
agents 
 Cells were incubated with cisplatin (1 to 10 μM) or doxorubicin (0.01 to 0.2 μM), 
for three weeks followed by a drug-free recovery period, in an attempt to isolate cell 
populations enriched in putative CSCs. NCI-H460 and A549 cells were plated at T75 
flasks, left to adhere during 24 hours and incubated with the drug. During three weeks, 
fresh medium with new drug was replaced every two days. After this time, drug was 
withdrawn and cells were left to recover. 
 Cell morphology was monitored and recorded throughout the experiment by optical 
microscopy (Olympus CK X 41).   
 
2.7. Colony-forming assay 
 This approach was used in an attempt to test the ability of single parental and drug-
selected resistant cells to survive and form colonies. In this assay, the cells are in an 
adverse environment because they are separated from each other and cells possessing 
stemness properties will be more prone to survive and generate a tumour cell colony by 
itself [31, 35]. 
 Single-cell suspension of parental cells and cisplatin-resistant cell variant B were 
obtained using TrypLE™ Express. 300 cells were plated per 7cm Petri dish in triplicate. 
Cells were left to adhere for 24 hours, after which cells were either incubated with 
complete RPMI medium (controls) or with 1 μM of Cisplatin for 48 hours. Following this 
incubation, the media was replaced with drug-free complete RPMI medium until colonies 
containing at least 50 cells were visible (which took approximately 10 days). During this 
time period, medium was replaced twice a week. At the end of the assay, the medium was 
withdrawn, each Petri dish washed twice with PBS, cells fixed with methanol (Fisher 
Chemical) and 0.5% (w/v) crystal violet solution used to stain the colonies. The colonies 
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were visually counted and results are shown as mean ± SD of three independent 
experiments performed in triplicate.  
 
2.8. Chicken embryo chorioallantoic membrane (CAM) assay 
The chicken embryo chorioallantoic membrane (CAM) is an extra-embryonic 
membrane that serves as a gas exchange surface and its function is supported by a dense 
capillary network, which provides a uniquely supportive environment for primary tumour 
formation [123]. As the cchicken embryo is naturally immunodeficient and the CAM is 
easily accessible for manipulation and observation, this model provides an adequate 
environment to grow transplants from various cell lines.  
The CAM in vivo assay was, therefore, performed to evaluate the tumourigenesis of 
cisplatin-resistant cell variant B versus NCI-H460 parental cells. Single cell suspensions of 
these cells were prepared and the CAM assay was performed by Marta Teixeira Pinto at 
the “In vivo Choriallantoic Membrane (CAM) Assays Unit” at IPATIMUP, as previously 
described with some modifications [124, 125]. Briefly, fertilized chick (Gallus gallus) eggs 
obtained from commercial sources were incubated horizontally at 37.8°C in a humidified 
atmosphere. After 3 days a square window was opened in the shell after removal of 1.5-2 
mL of albumen to allow detachment of the developing CAM. The window was sealed with 
a transparent adhesive tape and the eggs returned to the incubator. On day 10, single cell 
suspensions of both populations were prepared and 1 x 10
6
, 1 x 10
5 
and 1 x 10
4 
cells were 
inoculated into a silicone ring placed on top of the CAM. Six chicken embryos were used 
for each condition Tumours were allowed to grow for 7 days at which time the embryos 
were euthanized. The resulting tumours were then excised from the embryos, together with 
the surrounding CAM, and photographed ex ovo under a stereoscope (Olympus, SZX16 
coupled with a DP71 camera) at 2x magnification.  
 
2.9. Western Blot 
 Western blot is a technique by which specific antigens can be distinguished in a 
complex protein mixture. First, proteins are fractionated in polyacrylamide gels and the 
resulting pattern is then electrophoretically transferred to nitrocellulose sheets. An 
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antibody is used for the detection on the solid phase, and visualization is due to 
autoradiography [126]. Western blot was performed to identify possible targets involved in 
chemoresistance mechanisms present in the putative CSC enriched populations. 
2.9.1. Cell lysates  
 Cell lysates were prepared using Lytic Cell M as lysis buffer solution, containing 
both protease (Roche) and phosphatase inhibitors to protect protein from degradation 
during the extraction procedure. After washing the cells twice with PBS, lysis buffer was 
added and incubated with plated cells during 15 minutes on ace. After this time the cells 
were scraped in the presence of the lysis buffer solution to help the lysing action. 
 
2.9.2. Protein quantification assay 
 The cell lysates were then quantified using a quantification kit (BioRad) based on 
the Bradford dye-binding methodology, according to the manufacturer’s instructions. 
 
2.9.3. Sodium Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
 After quantification, 30 μg protein extracts were mixed with laemmli sample buffer 
that contains 1 M Tris-hydrogen chloride (HCl) pH 6.8, 40% glycerol, 5% sodium dodecyl 
sulphate (SDS), β-mercaptoethanol 14.3 M and 1% bromophenol blue. The prepared 
samples were then heated to 95 ºC during 5 minutes. The proteins were separated by their 
molecular weight by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) through a 7% or 12% of polyacrylamide gel, depending on the molecular weight of 
the proteins of interest. The resolving gel was composed by 30% acrylamide mix 
(BioRad), 1.5 M Tris-HCl pH 8.8, 10% SDS, 10% ammonium persulfate (APS) and 
tetramethylethylenediamine (TEMED). The stacking gel had the same composition except 
for the Tris-HCl, 1 M Tris-HCl pH 6.8 was used in this case. The electrophoresis was 
performed with 10x Tris/Glycine/SDS buffer (BioRad) under 60-100 V during 
approximately 120 minutes.  
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2.9.4. Western blotting  
 After protein electrophoresis, the proteins were electrotransfered from the gel to a 
hybond-C nitrocellulose membrane (Amersham). The transference was performed with 
10x Tris/Glycine/SDS and 20% of methanol (Fisher Chemical) under 100 V during 
approximately 90 minutes. To verify the efficiency of the transference process, the 
membrane was submerged in Ponceau S, which binds to proteins. The membrane was then 
washed three times with Tris buffer saline - tween (TBS-T) for 10 minutes to deplete the 
presence of Ponceau S. To inhibit the antibodies-unspecific bindings, the membrane was 
blocked with 5% of powdered milk diluted in TBS-T during 60 minutes at room 
temperature under shaking. In order to detect the presence of proteins of interest, 
immunoblotting was performed using mouse-anti P-glicoprotein (Pgp) (Sigma) at 1:500 
dilution, mouse-anti XIAP (BD transduction Laboratories) at 1:1000 dilution, mouse-anti 
P53 (Thermo Scientific) at 1:200 dilution, rabbit-anti B-cell lymphoma extra-large (Bcl-
XL ) (Santa Cruz) at 1:200 dilution, mouse-anti B-cell lymphoma 2 (Bcl 2) (Dako) at 
1:200 dilution (Table 2.1). All the antibody dilutions were performed with block solution. 
The period of antibody incubation was 60 minutes at room temperature under gently 
shaking. After this, the membrane was washed three times for 10 minutes with TBS-T 
under vigorous shaking. After exposure to the specific secondary antibodies (donkey anti-
goat, goat anti-mouse and goat anti-rabbit, all from Santa Cruz), diluted 1:2000 in block 
solution and incubated for 60 minutes at room temperature under gentle shaking, the 
proteins were visualized using an electrochemiluminescence (ECL) chemiluminescent 
detection kit (GE Healthcare). The housekeeping protein β-actin (Santa Cruz) was used as 
a loading control, at 1:2000 dilution in block solution for 60 minutes incubation at room 
temperature under gently shaking. When necessary, a stripping process was used in order 
to deplete all the protein bindings to the membrane. The stripping solution was composed 
by β-mercaptoetanol, 10% SDS and 1 M Tris-HCl, pH 6.7. 
 The pictures were taken in a quemidoc system (Bio-Rad). Protein normalization 
was performed using the Quantity One Basic software (Bio-Rad).  
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Table  2.1 - List of antibodies used. 
Primary antibody Dilution Animal Origin Commercialized by 
Pgp 1:500 Mouse Sigma-Aldrich 
XIAP 1:1000 Mouse BD transduction 
Laboratories 
P53 1:200 Mouse Thermo Scientific 
Bcl-XL 1:200 Rabbit Santa Cruz 
Bcl 2 1:200 Mouse Dako 
Β-actin 1:2000 Goat Santa Cruz 
 
2.10. Gene expression analysis 
2.10.1. RNA extraction  
 Total RNA was extracted from parental and cisplatin-resistant cells using 1 mL of 
TRI Reagent (Ambion) for 5-10x10
6
 cells by repetitive pipetting. After cell lysis, 0.2 mL 
of chloroform was added and each tube shook vigorously for 15 seconds, left for 5 minutes 
at room temperature and centrifuged at 12,000 × g for 15 minutes at 4 ºC. This step 
allowed the separation of RNA (aqueous phase), DNA (interphase) and proteins and lipids 
(organic phase). The aqueous phase was transferred to a fresh tube and 0.5 mL of 
isopropanol added and mixed. The samples were left for 10 minutes at room temperature 
and then centrifuged at 12,000 x g for 10 minutes at 4 ºC. This step allowed the 
precipitation of RNA. Supernatant was carefully removed and the pellet washed with 75% 
of ethanol (Panreac). After this stage, the samples were vortexed and centrifuged at 7,500 x 
g for 5 minutes at 4 ºC. The RNA pellet was briefly air dried. The pellet was next dissolved 
in 23 μL pre-warmed (55-60 ºC) RNase/DNase-free water (Gibco) by repeated pipetting 
and further incubated at 55-60 ºC for 10 minutes to facilitate dissolution.   
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2.10.2. RNA Treatment with DNase 
 Possible genomic DNA contamination of RNA samples was eliminated upon 
DNase treatment using the TURBO DNA-free kit (Ambion), according to the 
manufacturer’s instructions. Briefly, 10 μg RNA were incubated with 1μL TURBO DNase, 
TURBO DNase buffer and RNase/DNase-free water to a final volume of 50 μL. The 
samples were incubated at 37 ºC for 30 minutes. After the incubation period, 0.1 volume 
DNase inactivation reagent (Ambion) was added and mixed with the samples in order to 
inactivate the enzyme. The samples were incubated at room temperature during 5 minutes 
when the tubes were flicked 3 times to redisperse the DNase inactivation reagent. The 
samples were centrifuged at 10,000 x g for 1.5 minutes and the RNA (in supernatant) 
transferred to a fresh tube.  
 
2.10.3. RNA quantification 
 RNA was quantified using a NanoDrop spectrophotometer (ND 1000, Thermo 
Scientific) with tND-1000 software (3.3.0 version). Ratios of A260/A280 were used to 
evaluate the purity of RNA extract and values of approximately 1.9 were considered of 
sufficient quality for RNA expression analysis. The formula used to calculate the 
concentration of RNA in µg/µL was: 
 
(A260 x 40 x dilution factor) / 1000 = [RNA] 
 
2.10.4. cDNA synthesis 
 After RNA sample been purified, the production of cDNA using ThermoScript for 
cDNA synthesis kit (ThermoSript) was the next step. A mix containing 1 µL of primer 
oligo d(T)20 and 1 µL of deoxyribonucleotides triphosphate (dNTPs) was added to 9 µL of 
each RNA sample and placed at 65 ºC for 5 minutes to denature samples, and then placed 
on ice. Next, a mix prepared on ice and containing 4 µL of cDNA synthesis buffer, 1 µL of 
0.1 M DTT, 1 µL of RNaseOUT (40 U/µL), 1 µL of DEPC-treated water and 1 µL of 
thermoscript RT (15 U/µL) was added to each denatured sample and transferred to a 
thermal cycler (MyCycle – Bio Rad) preheated to 55 ºC for 60 minutes, for cDNA 
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synthesis. The reaction was terminated through sample incubation at 85 ºC for 5 minutes. 1 
µL of Rnase H was added and incubated at 37 ºC for 20 minutes to eliminate the RNA. 
 
2.10.5. Real-Time quantitative PCR 
 Real-time quantitative reverse transcription PCR (qRT-PCR) is one of the most 
sensitive and accurate methods to quantifying variations in gene expression levels. This 
technique involves the reverse transcription (RT) of mRNA into cDNA and uses 
fluorescent report molecules to measure in real-time the subsequent amplification of cDNA 
by polymerase chain reaction (PCR) [127]. RT-PCR was performed to corroborate the 
possible chemoresistance mechanisms involved in the putative CSC enriched populations 
and to investigate the expression of stemness-related genes by assessing multidrug resistance 
gene 1 (MDR1), Bmi-1, SRY (sex determining region Y)-box 2 (Sox2), ABCG2 and Hprt1 
gene expression (Table 2.2). Primers for MDR1 and ABCG2 were designed by Almeida 
GM, Bmi-1 primers were designed according to Chaurasia et al [128], SOX2 primers 
adapted from Que et al [129]  and Hprt1 primers according to Almeida GM et al. [105]. 
 A mix containing QuantiTect SYBR Green PCR Master Mix (Applied Biosystems), 
forward and reverse primers and RNase-free water was added to 1 μL of template cDNA 
(1:20) and dispensed into the individual wells of a 96-well plate. The primers concentration 
was 150 pM for all the tested genes with exception of SOX 2, which was 300 pM. The 
plate was briefly centrifuged and reactions conducted in a real-time cycler (7500 FAST 
Real-Time PCR system, Applied Biosystems). The run method used was based on 2 
different stages, the holding stage and the cycling stage. In the holding stage the 
temperature increased from 25º C to 50º C and was maintained during 2 minutes and 
increased again to 95º C being maintained during 10 minutes. In the cycling stage, the 
temperature was maintained at 95º C for 15 seconds followed by a decrease in temperature 
to 60º C which was maintained for 1 minute. The number of cycles was 40. Data were 
analyzed using the associated 7500 software, v. 2.0.5. 
Gene expression was quantified by the standard curve method [130], whereby a 
standard curve is constructed by amplifying known amounts of serially diluted cDNA in a 
parallel group of reactions run under identical conditions to the samples. Standard curves 
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were undertaken for each gene that was being analysed in each PCR run and was used for 
calculation of PCR amplification efficiency and quantification of target cDNA.  
The value of both target and housekeeping genes from each sample was determined 
from the respective standard curve equation and the target value divided by the 
endogenous reference value to obtain a normalised target value independent from the 
starting amount or material. Non-template controls (NTC) were also used to ascertain that 
no DNA contamination was present in the samples. The existence of only one melting 
temperature/peak in all samples indicated the presence of a single amplification product. 
The absence of an amplification product in the NTC indicated that there was no external 
DNA contamination in the PCR mix and no primer dimer formation, which would also 
result in a fluorescence peak. 
 
Table  2.2 - Primer sequence and expected PCR product length. 
Gene 
 
Forward Primer  
(5’ – 3’) 
Reverse Primer  
(5’-3’) 
Length 
bp 
MDR1 CCGCAATGGAGGAGCAAAGAAG GTCAAGCCAATTTGAATAGCGAAACA 124 
Bmi-1 CCACCTGATGTGTGTGCTTTG TTCAGTAGTGGTCTGGTCTTGT 162 
SOX 2 AACGGCTCGCCCACCTACAGC AGTGGGAGGAAGAGGTAACC 130 
ABCG2 GGATGTCTAAGCAGGGACGAACAAA GCCAATAAGGTGAGGCTATCAAACAAC 91 
Hprt1 GCAGACTTTGCTTTCCTTGGTCAG GTCTGGCTTATATCCAACACTTCGTG 103 
 
2.10. Statistical analysis 
 The t-test was used for the statistical analysis always to compare two averages. The 
values compared had equal sizes, were always independent and the variances of the two 
populations were equal. 
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3.  Results 
 Cancer stem-like cells are believed to be partially responsible for tumour 
chemoresistance. The aim of the current project was to isolate and characterize lung CSCs 
in terms of chemoresistance mechanisms and to identify potential therapeutic targets to 
overcome chemoresistance in these cells. 
 
3.1. Isolation of putative lung CSCs (ABCG2
+
) by fluorescence activated 
cell sorting 
As a first step, ABCG2 marker was choosen to isolate a putative lung CSC 
population through fluorescence activated cell sorting (FACS). 
Cell line NCI-H460 was labelled with an antibody for the cell surface protein 
ABCG2, upon which FACS was performed to isolate the ABCG2 positive and negative 
sub-populations. Purity of the cell sub-populations was verified by flow cytometry 
immediately after FACS sorting. The two sub-populations were successfully separated 
although purity of the ABCG2
+
 sub-population was only between 70 and 86% (Table 3.1) 
Nevertheless, a purity of around 100% was consistently obtained for the ABCG2
- 
subpopulation. The cell sorted sub-populations were then expanded in vitro until sufficient 
cells were available to perform cell growth/viability assays to assess response to 
chemotherapeutic drugs. 
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Table  3.1 - Cell sorting performed in NCI-H460 cell line using ABCG2 antibody. Three independent cell 
sorting experiments were performed. 
Cell 
sorting 
ABCG2 
expression 
Number of 
ABCG2
-
 
cells 
Purity of 
ABCG2
-
 
sorted cells 
Number of 
ABCG2
+
 
cells 
Purity of 
ABCG2
+
 
sorted cells 
1 16 % 321 000 100% 262 000 70% 
2 14 % 93 000 100% 41 900 79% 
3 10 % 105 000 99% 30 500 86% 
 
3.2. Chemosensitivity of NCI-H460 cells and ABCG2
+
/ABCG2
-
 sorted cell 
populations 
 After lung tumour cells being sorted, it was wanted to understand if there were 
differences in drug response of ABCG2
+
, ABCG2
-
 and NCI-H460 populations. To 
accomplish that, cell growth/viability assay were performed. 
3.2.1. Optimization of the starting conditions for the cell growth/viability assays 
Preliminary assays were performed to determine if the chosen cell growth/viability 
assays used were reliable (i.e. fluorescence/absorbance directly proportional to the number 
of cells) and sensitive enough (i.e. the range of numbers of cells for which this linearity is 
maintained). Cells were plated at different seeding densities and resazurin-based and SRB 
assays performed following 24 hours. A direct correlation was determined between 
fluorescence/absorbance and the number of NCI-H460 cells (Pearson correlation – 0.99), 
confirming the reliability of the assay. Moreover, both assays were sensitive within the 
range of 250 to 16,000 cells (Figure 3.1).  
For determination of the optimal starting cell density, cells were plated in 96-well 
microplates at densities of 250 – 16,000 cells per well and left to adhere for 24 hours, as 
above, and processed for resazurin-based and SRB assays following a further 48 hour 
incubation  (Figure 3.2 and 3.3, respectively). Results show that the linearity between 
fluorescence/absorbance measures and the number of cells is only maintained if up to 4000 
36 
 
cells/well are initially plated. A plateau is reached when cell seeding densities above 4000 
cells/well are used, indicating that the cells have reached confluence or that the assay has 
saturated. Therefore, a seeding density of 2,000 cells per well was chosen for all 
subsequent experiments using cell growth/viability assays, in order to assure that control 
cells would still be in exponential growth at the end of the 48 hours of the assay.  
 
 
  
Figure  3.1- Sensitivity of the cell growth/viability assays. Cells were seeded at different densities (from 250 
to 16,000 cells/well) in a 96-well plate (four replicate wells per cell density) and incubated for 24 hours prior 
to processing for the resazurin-based (A) and SRB (B) assays. 
 
A 
B 
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Figure  3.2 - Determination of the optimal starting cell density. Cells were seeded at different densities 
(from 250 to 16,000 cells) in a 96-well plate (four replicate wells per cell density) and left to adhere during 
24 hours. After 48 hours resazurin-based assay was performed. 
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Figure  3.3 - Determination of the optimal starting cell density. Cells were seeded at different densities 
(from 250 to 16,000 cells) in a 96-well plate (four replicate wells per cell density) and left to adhere during 
24 hours. After 48 hours SRB was performed. 
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3.2.2. Cell growth/viability assays 
Cell growth/viability assays in response to different chemotherapeutic agents were 
performed in order to measure possible differences in chemoresistance between parental, 
ABCG2
+
 and ABCG2
-
 sub-populations of cells. No significant differences in drug 
response were observed between these populations of cells (Figure 3.4). 
 
  
  
Figure  3.4 - Cell survival upon incubation with chemotherapeutic drugs (cisplatin, gemcitabine, 5-FU and 
doxorubicin) in NCI-H460 parental cells and the ABCG2+ and ABCG2- sub-populations, was assessed by 
resazurin-based (A) and SRB (B) assays. Results are the mean ± SD of three independent experiments (each 
from an independent cell sorting experiment). 
A 
B 
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3.2.3. Expression of ABCG2 in NCI-H460 cell sorted populations following in vitro 
expansion 
To understand the evolution of sorted population, at the time of cell 
growth/viability assay were performed, expression of ABCG2 in the ABCG2
+
 and 
ABCG2
-
 cell sorted populations was assessed following nine days of in vitro expansion 
(after FACS). Results show that both sub-populations of sorted cells presented a similar 
percentage of ABCG2 expression as originally found in the parental cell line (Figure 3.5), 
which limits the use of this approach for subsequent studies on putative lung CSCs. 
 
Figure  3.5 – Fluorescence activated cell sorting for the ABCG2 marker was performed in NCI-H460 cell 
line. ABCG2 was present in 16% of the NCI-H460 cells when compared with the IgG-PE control. Nine days 
upon cell sorting, the percentage of ABCG2 in each sorted sub-populations was assessed. The ABCG2
+
 sub-
population of cells possessed 15.7% of ABCG2 and the ABCG2
-
 sub-population exhibited 12.2% of cells 
expressing this protein. Results shown were obtained from cell sorting experiment number 1.  
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3.3 Enrichment of putative lung CSCs by incubation with 
chemotherapeutic agents 
 In order to verify if incubation with chemotherapeutic drugs may result in an 
enrichment of cancer stem-like cells and, consequently, a more resistant sub-population of 
cells, two lung cancer cell lines (NCI-H460 and A549) were exposed to chemotherapeutic 
drugs commonly used in the clinic. The A549 lung cell line was exposed to cisplatin (10 
μM) and to doxorubicin (0.1 μM) for three weeks followed by a drug-free recovery period 
(three to four weeks). The NCI-H460 lung cancer cell line was exposed to cisplatin (1 μM 
and 2 μM) and to doxorubicin (0.05 μM) for three weeks followed by a drug-free recovery 
period (three to four weeks).  
 
3.3.1. Assessment of cell morphology 
Cell morphology during the three week incubation time with the drugs and during 
the drug-free recovery period was monitored by optical microscopy. It was observed that 
drug treatment led to a transient alteration in cell morphology in both cell lines, whereby 
cells acquired a more mesenchymal-like structure at 5 to 7 days upon drug incubation, 
depending on the cell line and on the chemotherapeutic agent. When the drug was 
withdrawn, the cells re-acquired their original epithelial morphology within 6 to 14 days 
following drug withdrawal (Figures 3.6, 3.7, 3.8 and 3.9). 
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Figure  3.6 - Cell morphology changes observed upon incubation of A549 cells with 10 µM of the 
chemotherapeutic drug cisplatin (for three weeks) followed by a drug-free recovery period (of several 
weeks).  
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Figure  3.7 - Cell morphology changes observed upon incubation of A549 cells with 0.1 µM of the 
chemotherapeutic drug doxorubicin (for three weeks) followed by a drug-free recovery period (of several 
weeks).  
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Figure  3.8 - Cell morphology changes observed upon incubation of NCI-H460 cells with 2 µM of the 
chemotherapeutic drug cisplatin (for three weeks) followed by a drug-free recovery period (of several 
weeks).  
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Figure  3.9 - Cell morphology changes observed upon incubation of NCI-H460 cells with 0.05 µM of the 
chemotherapeutic drug doxorubicin (for three weeks) followed by a drug-free recovery period (of several 
weeks).  
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3.3.2. Assessment of drug response in the drug-selected populations  
 Cell growth/viability assays were performed in all the drug-selected populations of 
cells in order to assess differential drug response when compared with the parental cell 
lines they originated from. All the experiences were performed after the three week drug 
exposure followed by the drug-free recover period. Cell growth/viability assays were 
always performed using both resazurin-based and SRB assays. 
 
The drug selected A549 cells derived from long term exposure to doxorubicin (0.1 
µM) did not show alterations in terms of drug response when compared with the parental 
cell line (Figure 3.10) after 48 hours of doxorubicin treatment (0 to 0.2 µM).  
Cisplatin-selected A549 cells (10 µM) also did not show alterations in terms of 
drug response when compared with A549 parental cells, but only one experience was 
performed (data not shown). 
 
NCI-H460 cells incubated with 0.05 μM doxorubicin for a three week period did 
not present increased resistance to doxorubicin (0 to 0.1 µM) during 48 hours when 
compared to the parental cells (Figure 3.11). However, NCI-H460 cells selected upon a 
long-term incubation with 1 and 2 μM of cisplatin presented a significant increase in 
resistance towards the selecting agent, when compared to the parental cells (Figures 3.12 
and 3.13, respectively). From NCI-H460 exposure to 1 and 2 µM of cisplatin resulted what 
we name from now on as cisplatin resistant cell variant A (CRCVA) and cisplatin-resistant 
cell variant B (CRCVB), respectively. 
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Figure  3.10 – Percentage of cell growth following 48 hour incubation with doxorubicin (0 to 0.2 μM) in 
A549 parental cells and doxorubicin-selected (0.1 µM) A549 cells, was assessed by resazurin-based (A) and 
SRB (B) assays. Results are the mean of three replicate measurements per sample, performed in two 
independent experiments. 
 
A 
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Figure  3.11 – Percentage cell growth following 48 hour incubation with doxorubicin (0 to 0.1 μM) in NCI-
H460 parental cells and doxorubicin-selected (0.05 µM) NCI-H460 cells, was assessed by resazurin-based 
(A) and SRB (B) assays. Results are the mean of two independent experiments. 
 
B 
A 
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Figure  3.12 – Cisplatin-resistant cell variant A (derived from NCI-H460 when treated with 1 μM of 
cisplatin) and parental cells (NCI-H460) were incubated with different concentrations of cisplatin (0 to5 μM) 
for 48 hours. The percentage of cell growth was assessed with resazurin-based (A) and SRB (B) assays. 
Results are the mean ± SD of three independent experiments, * P < 0.05 and ** P < 0.01. 
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Figure  3.13 – Cisplatin-resistant cell variant B (derived from NCI-H460 when treated with 2 μM of 
cisplatin) and parental cells (NCI-H460) were incubated with different concentrations of cisplatin (0 to 5 μM) 
for 48 hours. The percentage of cell growth was assessed with resazurin-based (A) and SRB (B) assays. 
Results are the mean ± SD of three independent experiments, * P < 0.05 and ** P < 0.01. 
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Only NCI-H460 cells resulting from long-term exposure to 1 μM and 2 μM of 
cisplatin possessed increased survival ability towards the selecting agent when compared 
with the parental cells. This increased cisplatin-resistance in cisplatin-resistant cell variant 
B (CRCVB) was further confirmed by the clonogenic assay, whereby upon incubation with 
1 μM of cisplatin the obtained % cell survival was of 5 ± 4.6 and 32 ± 6.7 for parental and 
CRCVB cells, respectively (average of three independent experiments, performed in 
triplicate). In addition, response to other chemotherapeutic agents, for which cells had not 
been previously exposed to, was also assessed (Figure 3.14). Results show that cisplatin 
long term exposure led to increased resistance towards the selecting drug but also to 
gemcitabine and doxorubicin (although no statistical significant difference was observed in 
the latter), although not for 5-FU.  
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Figure  3.14 - Drug-selected and NCI-H460 parental cells were incubated with different concentrations of 
gemcitabine, 5-FU and doxorubicin. The percentage of cell survival was assessed with a resazurin-based (A) 
and the SRB (B) assays. Results are the mean ± SD of three independent experiments, * P < 0.05 and ** P < 
0.01. 
A 
B 
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3.3.3. Assessment of chemoresistance upon novel drug exposure of the drug-selected 
cell variants 
The cisplatin-resistant cell variant B and NCI-H460-doxorubicin treated (0.05 μM) 
cells were further exposed to a new round of incubation (three week drug exposure 
followed by a drug-free recover period) with chemotherapeutic agents. Cisplatin-resistant 
cell variant B was incubated with 5 μM of cisplatin (resulting the cisplatin-resistant cell 
variant C) and NCI-H460-doxorubicin treated cells with 0.1 μM of doxorubicin (resulting 
the doxorubicin-resistant cell variant A), for three weeks followed by a drug-free recovery 
period (three to four weeks). The transient alteration in cell morphology was again verified 
(data not shown).  
The effects of these new drug-incubation and recovery periods in drug resistance 
were further tested. Cisplatin-resistant cell variant C showed to be characteristically more 
resistant than the parental cells, although very similar to the cisplatin-resistant cell variant 
B, from which it originated (Figure 3.15). GI50 of cisplatin was calculated to NCI-H460 
parental (GI50 ≈ 1 μM), CRCVB (GI50 ≈ 4.6 μM) and CRCVC (GI50 ≈ 4.7 μM). A five 
times higher concentration of cisplatin was required to inhibit the cell growth of CRCVB 
and CRCVC in 50 % when compared to the NCI-H460 parental cells. 
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Figure  3.15 – Cisplatin-resistant cell variant C (derived from cisplatin-resistant cell variant B when treated 
with 5 μM of cisplatin), cisplatin-resistant cell variant B and parental cells (NCI-H460) were incubated with 
different concentrations of cisplatin (0 to 10 µM) for 48 hours. The percentage of cell growth was assessed 
with resazurin-based (A) and SRB (B) assays. Results are the mean ± SD of three independent experiments, * 
P < 0.05, *** P < 0.001 and **** P < 0.0001 (calculated between cisplatin-resistant cell variant c and 
parental cells).  
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The new cycle of therapy induced in the doxorubicin-treated cells by long-term 
exposure to 0.1 μM of doxorubicin resulted in a sub-population of significantly more 
resistant cells when compared to the parental NCI-H460 cells (Figure 3.16).  
 
  
  
Figure  3.16 – Doxorubicin-resistant cell variant A (derived from doxorubicin-treated cells when treated 
with 0.1 μM of doxorubicin) and parental cells (NCI-H460) were incubated with different concentrations of 
doxorubicin (0 to 0.2 μM) for 48 hours. The percentage of cell growth was assessed with resazurin-based (A) 
and SRB (B) assays. Results are the mean ± SD of three independent experiments, * P < 0.05 and ** P < 
0.01. 
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From all drug-selected cell variants, cisplatin-resistant cell variant A (CRCVA) and 
cisplatin-resistant cell variant B (CRCVB) were choosen for all subsequent studies.   
 
3.4. Assessment of expression of proteins involved in drug resistance  
 In an attempt to identify the proteins conferring increased drug resistance to the 
resistant NCI-H460 cell variants (when compared to the parental cells), expression of 
proteins involved in drug resistance (Pgp, XIAP, Bcl-XL, Bcl 2) was assessed by Western 
blot. Increased expression of the apoptosis-related proteins Bcl-XL and XIAP in CRCVB 
and of the drug efflux pump P-glycoprotein (PgP) in CRCVA was verified when those 
populations were compared to the parental NCI-H460 cell line (figures 3.17 and 3.18). 
 
 
 
Figure  3.17 – Western blot to XIAP, Bcl 2, Bcl-XL and to Pgp were performed using two independents 
extractions of total protein from each population of cells (A – cisplatin-resistant cell variant A; B – cisplatin 
resistant cell variant B). Actin was used as a loading control. 
XIAP 
Bcl 2 
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Figure  3.18 – Quantification of Pgp, XIAP and Bcl-XL expression using actin as a loading control. Each 
value represents the mean of two independent samples tested at least in two different occasions.  
 
 
 To determine how CRCVA, CRCVB and NCI-H460 parental cells responded after 
24 hours of 5 µM of cisplatin exposure in terms of P53 expression  and Pgp induction, the 
levels of P53 and Pgp were assessed by Western blot. After drug exposure, up-regulation 
of P53 was found in NCI-H460 parental and cisplatin resistant variants, although this 
response seemed increased in the parental cells when compared to CRCVA and CRCVB 
treated cells (Figure 3.19). Cisplatin incubation with CRCVA was capable of inducing up-
regulation of Pgp, although no expression differences were found relatively to the other 
tested populations (Figure 3.19). 
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Figure  3.19 - Western blot was perfomed to P53 and Pgp proteins in CRCVA, CRCVB and NCI-H460 
parental cells. After 24 hours of cisplatin exposure, all the treated populations up-regulated P53, althuogh a 
higher overexpression was found between the NCI-H460 parental cells. Only the CRCVA population was 
capable to up-regulate Pgp protein after 24 hours of drug exposure. Ctr – control cells; Trt – treated cells. 
Results represent one single experiment. 
 
3.5. Stemness assessment of the cisplatin-selected cell variants 
To verify if cisplatin long term exposure enriched a population with stem-like 
properties the presence of stem-like cell markers, such as ABCG2, CD133 and Sox 2, Bmi-
1, were assessed  by flow cytometry and qRT-PCR in both NCI-H460 cisplatin-resistant 
variants and parental cells. 
3.5.1. Analysis of ABCG2 expression by flow cytometry  
 The percentage of expression of ABCG2 and CD133 stem cell markers was 
assessed by flow cytometry, to verify the presence of stem-like cell properties in the 
cisplatin-resistant cells (Figure 3.20). An apparent increase in the percentage of cells 
expressing the putative stem cell marker ABCG2 (Figure 3.20) was observed for both cell 
variants, although this was only statistically significant for the cisplatin-resistant cell 
variant B (Figure 3.21). Expression of CD133 also appeared to increase in the drug-
resistant cell variants when compared to the parental cells, although the percentage of cells 
expressing this marker was only around 1% and may not be biologically relevant (data not 
shown).   
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Figure  3.20 - Flow cytometry analysis for ABCG2 was performed in NCI-H460 parental cells (A), 
cisplatin-resistant cell variant A (B) and in cisplatin-resistant cell variant B (C). Results shown are 
representative of three independent experiments. 
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Figure  3.21 – Percentage of cells expressing ABCG2 was assessed by flow cytometry analysis in NCI-
H460 parental cells and in cisplatin-resistant cell variants A and B, when compared to cells labelled with 
IgG-PE of each population. Results are the mean ± SD of three independent experiments, * P < 0.05. 
 
3.4.2. Colony-forming assay 
The colony-forming assay was perfomed to assess whether the cisplatin-resistant 
cells possessed enhaced stemness capacity when compared to NCI-H460 parental cells, as 
determined by assessing the % of plating efficiency. Plating efficiency was calculated 
between the number of colonies generated from each population, taking into account the 
initial number of cells seeded per Petri dish. Results obtained from three independent 
experiments (performed in triplicate) revealed only small differences in % plating 
efficiency between the parental and CRCVB cells (54.7 ± 3.6 and 63.1 % ± 7.6, 
respectively). 
 
3.4.3. Tumourigenesis assay 
An in vivo tumourigenesis assay, using the chicken embryo, was also performed in 
the NCI-H460 and CRCVB cells. 
 Different numbers of cells (1x10
6
, 1x10
5
, 1x10
4
) from each CRCVB and parental 
population were inoculated on top of the CAM. No differences in the number of tumours 
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formed between CRCVB and parental cells were verified after 1x10
6
 and 1x10
5
 cells were 
inoculated. When 1x10
4
 cells were inoculated, CRCVB possessed capacity to generate 
tumours whereas NCI-H460 parental cells did not (Table 3.3). A tendency for CRCVB 
cells to generate bigger tumours than parental cells, after inoculation of 1x10
6
 cells, was 
also observed (Figure 3.22). Six chicken embryos were used for each condition, however 
many chicken embryos died during the experiment. 
 
 
Table  3.2 - Tumourigenesis of CRCVB and NCI-H460 parental cells. The capacity of CRCVB and parental 
cells to generate tumours in vivo was assessed by CAM model. The number of chicken embryos presenting a 
CAM tumour 7 days after cell inoculation is represented relatively to the final numbers of surviving chicken 
embryos. Results are representative of one single experiment. 
Condition Inoculated cells NCI-H460 cells CRCVB 
1 1x10
6
 2/2 4/4 
2 1x10
5
 2/3 2/3 
3 1x10
4
 0/3 4/5 
 
 
 
 
 
Figure  3.22 – Tumour formation in CAM tissue. Seven days after 1x106 cells from NCI-H460 parental 
cells (A) and CRCVB (B) being inoculated on CAM, tissue was dissected and fixed and tumours observed. 
Images are representative of the results obtained in condition 1. 
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3.6. Assessment of expression of stemness and drug resistance-related 
genes  
 In order to quantify the presence of other stem cell markers in cisplatin-resistant 
cell variants, gene expression of Bmi-1, Sox2 and ABCG2 was assessed by RT-PCR. 
MDR1 gene expression was also measured to assess whether the increased Pgp expression 
verified in CRCVA was due to increased mRNA expression. Fold changes (FC) > 1.7 or < 
–1.7 (considered biologically relevant) were observed in ABCG2 and MDR1 genes 
expression in both CRCVA and especially in CRCVB. Expression of Sox2 was decreased 
in CRCVA, with a FC of -2 (Table 3.4).  
 
 
Table  3.3 - Quantifications of gene expression through RT-PCR. ABCG2, Sox2, MDR1 and Bmi-1 genes 
expression was quantified in CRCVA and CRCVB relatively to the amount of all tested genes in NCI-H460 
parental cells. Hprt1 gene was used as a loading control. Results are the mean ± SD of three independent 
experiments. 
Gene CRCVA CRCVB 
ABCG2 1.7 ± 0.2 2.2 ± 0.1 
Sox2 -2.2 ± 0.1 1.1 ± 0.5 
MDR1 5.9 ± 2.6 10.2 ± 1.8 
BMI1 1.5 ± 0.4 1.6 ± 0.3 
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4. Discussion 
 Tumour drug resistance is a major issue in the management of lung cancer, the 
worldwide leading cause of cancer-related deaths, as almost all lung tumours are either 
intrinsically resistant or quickly develop acquired resistance to chemotherapeutic drugs 
[131]. Since it is currently believed that CSCs are partially responsible for tumour drug 
resistance, we aimed to identify some of the drug resistance mechanisms in putative lung 
CSCs in order to select appropriate targets to chemosensitize those cells and improve 
patient survival.  
The SP phenotype is described as a stem cell property that has already been 
successfully used to identify lung cancer cells with stem-like properties [7]. As mentioned 
above, SP cells can be isolated by dual-wavelength flow cytometry because of their ability 
to efflux Hoechst dye, being this process mediated by ABCG2 protein. In this project, 
expression of ABCG2 was used to identify a putative lung CSC population. Human 
ABCG2 is the second member of the G subfamily of ABC transporters, which use cellular 
ATP to drive the transport of various substrates across cell membranes including drugs, 
metabolites and other compounds. ABCG2 was first cloned from doxorubicin-resistant 
human MCF-7 breast cancer cells and named as breast cancer resistance protein (BCRP) 
[132]. After fluorescence activated cell sorting it was found that this transmembrane 
protein was present in around 10 to 16% of NCI-H460 cells (Table 3.1). There was not a 
well-defined ABCG2
+
 population in the stained samples during cell sorting, making it 
difficult to select the appropriate gatings to identify the ABCG2
+
 sub-population. 
Consequently the purity level of the positive-sorted cells was affected. A high level of 
purity was preferred in detriment of increased final number of cells, which meant that the 
cells had to be further expanded following cell sorting. At this stage it was observed that 
the surviving sorted cells needed time to recover, and experiments to assess cell 
growth/viability in response to chemotherapeutic drugs were only possible to perform at 
least 9 days after cell sorting. Multiwell based cell viability/cell growth assays (resazurin-
based and SRB assays) were performed to assess drug response between cell sorted and 
parental populations. As shown in Figure 3.4, there were no differences between the NCI-
H460 parental cells, ABCG2
+
 and ABCG2
-
 sub-populations of cells in terms of resistance 
to the chemotherapeutic drug tested. When cell viability assays in the presence of drugs 
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were performed, the percentage of ABCG2 was similar in the ABCG2
+
 and ABCG2
-
 cell 
sorted populations and the parental cells (Figure 3.5), which may explain why no 
differences were found between those cell populations.   
 After cell sorting, the sub-populations rapidly reach the levels of ABCG2 
expression observed in the parental cells, impairing an appropriated study of a putative 
cancer-stem like cell population using this approach. It was expected that ABCG2
+
 cells 
were capable to give rise to the negative population. Although, the fact that the positive 
fraction of cells possess contaminant ABCG2
-
 cells (70-86% of purity) may justify the 
rapidly increase of ABCG2
-
 cells in the positive population. On the other hand, the 
appearance of ABCG2
+
 cells in negative-sorted population means that ABCG2
-
 cells 
possessed the ability to generate ABCG2
+
 cells, which was not expected. The same results 
were before observed for Patrawala et al, when ABCG2
+
 prostate cancer cells could 
generate ABCG2
-
 cells and ABCG2
-
 prostate cancer cells could also generate ABCG2
+
 
cells [133]. In the present study, repopulation of the original levels of cells expressing 
ABCG2 in ABCG2
+
 population impaired the study of a putative cancer-stem like cell 
population.  
 One of the major properties of CSCs is their increased ability to survive in the 
presence of chemotherapeutic drugs, due to the presence of a number of genetic and 
cellular adaptations [80]. Conventional therapies appear to be capable of eliminating most 
of the cells in a tumour but not CSCs [13]. Bearing this in mind, cisplatin or doxorubicin 
incubation was attempted as a means of enrichment of a putative CSC population. We 
continuously exposed A549 and NCI-H460 cell lines to cisplatin or doxorubicin using their 
IG50 (defined as the concentration corresponding to 50% of growth inhibition) for three 
weeks followed by a drug-free recovery period. The recovery period was variable from 
each group of treated cells (3-5 weeks) and during this time the cells seemed to have a very 
low rate of cell divisions. Cell morphology was monitored and recorded throughout the 
experiment. It was observed that cells acquired a mesenchymal-like structure when 
exposed to the drugs and recovered their initial morphology after the chemotherapeutic 
agent was withdrawn (Figures 3.6, 3.7, 3.8 and 3.9). The observed morphological changes 
are consistent with EMT, a process by which epithelial cells undergo morphological 
changes such as acquire an elongated fibroblastic phenotype [134]. EMT induced by 
chemotherapy has already been described in the literature, being preferentially related with 
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ionising radiation or reactive oxygen species capable of inducing changes in morphology, 
cell adhesion and cell motility in a process that seems to be linked with radiation-induced 
fibrosis [112]. Recent studies correlated EMT induction by chemotherapy. Enhanced 
invasiveness and motility after cisplatin treatment were reported and specific microRNAs 
were linked with such regulation [135]. Some reports strongly suggest that EMT could 
generate stem-like cells, however the molecular mechanisms responsible for that process 
are not fully understood. CSCs share some characteristics with cells that have undergone 
EMT, like invasiveness and metastatic potential and drug resistance [136]. In fact, EMT 
and drug resistance phenotype seem to be extremely correlated. In some cases, the 
suppression of transcription factors involved in EMT resulted in chemo-sensitivity [137]. 
In other studies, cells that were particularly chemo-resistant possessed increased EMT 
markers [116]. The mechanism by which EMT confers resistance to therapy seems to be 
correlated with protecting the cells from undergoing apoptosis [138]. The presence of EMT 
has not yet been confirmed in our cells, although some indications of a possible epithelial-
to-mesenchymal transition through the acquisition of an elongated mesenchymal-like 
structure have been recorded.  
 Response towards chemotherapeutic drugs was assessed in the drug-selected cell 
populations (following a three to five week drug-free recovery period) and compared with 
their respective parental cells. During the treatment time the majority of the parental cells 
died and only a subpopulation of cells survived. Even so, the A549 cells resulting from 
long term exposure to cisplatin (data not shown) or doxorubicin (Figure 3.10) did not show 
an enhanced resistance capacity to the selecting agent when compared to the parental cell 
line. Possibly, a more resistant population was enriched, although when cells recovered 
from drug treatment and started to proliferate they rapidly resemble the original 
population. Cisplatin exposure on NCI-H460 cells resulted in cisplatin-resistant cell variant 
A (CRCVA; exposed to 1μM of cisplatin) and cisplatin-resistant cell variant B (CRCVB; 
exposed to 2 μM of cisplatin) with significant increased resistance towards the selecting 
drug (Figures 3.12, 3.13, respectively) but also resistance to doxorubicin and gemcitabine, 
although not for 5-FU (Figure 3.14). The mechanism of action of all these drugs is related 
with impairment of DNA replication and consequently cell death by apoptosis. The only 
difference is that 5-FU most described mechanism of action does not interact directly with 
DNA, but by inhibition of the key enzyme of pyrimidine synthesis, TS [110]. Results 
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suggest that the mechanisms behind resistance to the chemotherapeutic drugs observed in 
the NCI-H460 drug selected cells are insufficient to confer resistance towards 5-FU. Drug 
resistance of cisplatin-selected cell variants A and B were assessed and confirmed, by cell 
growth/viability assays, to be maintained over a period of time of approximately 4 months. 
However, 6 months later, when colony-forming assay was performed, CRCVB plated cells 
possessed increased capacity to survive to cisplatin treatment (32.3 % ± 6.7) than NCI-
H460 parental cells (5 % ± 4.6). These results corroborated the capacity of CRCVB to 
survive to cisplatin already assessed before by short-term cell growth/viability assays. In 
the case of NCI-H460-doxorubicin treated cells a very slight tendency to resist to the 
selecting drug than the parental population was verified, especially in resazurin-based 
assay (Figure 3.11). To test if this tendency was real NCI-H460-doxorubicin treated cells 
were exposed to a new cycle of therapy. The results revealed that the new period of 
therapy in NCI-H460-doxorubicin treated cells induced doxorubicin resistance when the 
resulted population (doxorubicin-resistant cell variant A - DRCVA) was compared to the 
original cells (Figure 3.16). We also exposed CRCVB to a new period of drug treatment to 
determine whether the resulting cell populations were even more drug resistant. The 
resulting cell population (cisplatin-resistant cell variant C - CRCVC) did not show 
increased resistance to cisplatin when compared to cisplatin-resistant cell variant B (Figure 
3.15). 
 Resistance to therapy can be intrinsic or acquired. When tumours possess the 
capacity to survive therapy from the start of chemotherapy they are considered as 
intrinsically resistant. When tumour developed drug resistance during therapy, their 
resistance has been acquired [139]. Accounting to obtained results, chemotherapy induced 
tumour resistance. Cisplatin treatment resulted in an enrichment of a more cisplatin-
resistant population than before, suggesting that resistance was acquired. However, it is not 
possible to understand if cisplatin treatment is responsible for enriching a pre-resistant sub-
population, or if incubation with cisplatin induced adaptable changes in the most unstable 
cells, acquiring mechanism of resistance. CRCVA and CRCVB were the populations 
chosen as models to proceed with the rest of work since they showed to possess increased 
capacity to survive to chemotherapeutic agents. 
 In an attempt to verify if the cisplatin-resistant cell variants possess stem-like 
properties, expression of ABCG2 and CD133 stem cell related markers were assessed. 
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CD133
+
 population and SP marked by ABCG2 are the most two important determinants of 
CSC phenotype for NCSLC [3, 7, 8]. In the present work, an increase in the % of cells 
expressing ABCG2 was found in both CRCVA and CRCVB when compared with NCI-
H460 parental cells, although this was only statistically significant for CRCVB (Figure 
3.21). The % of cells expressing CD133 also increased in CRCVB and CRCVA compared 
to parental cells, although these values were too low to attribute any relevant biological 
meaning. However, the percentage of cells expressing ABCG2 protein in CRCVA and 
especially in CRCVB after cisplatin exposure was found to be relevantly increased 
comparing the NCI-H460 parental cells (Figure 3.20). This was also confirmed when 
analysing ABCG2 gene expression levels by real-time qRT-PCR revealed to be up-
regulated both in CRCVA (1.7 ± 0.2 FC) and especially in CRCVB (2.2 ± 0.1 FC) (Table 
3.3). Hsieh et al, have already reported that cisplatin-resistant lung cancer cells possessed 
higher percentage of ABCG2 gene expression than the parental cell line. It is important to 
note that, in our study, different doses of cisplatin treatment resulted in different 
percentages of cells expressing ABCG2 protein. 
Accounting that ABCG2 expression by itself is not sufficient to validate a 
population with stem-like properties, other stem markers were evaluated in this study. The 
gene expression of Bmi-1, Sox2 and ABCG2 were assessed by qRT-PCR. Bmi-1, a 
transcriptional repressor from polycomb family, is required for the self-renewal and post-
natal maintenance of hematopoietic stem cells [140] and neural stem cells [141]. Bmi-1 
gene expression was found to be identically regulated between both resistant population 
and parental cells (Table 3.3). Sox2, an embryonic stem cell marker, was found to be up-
regulated in a lung carcinoma SP comparing to non-SP [142]. The same group also 
reported that knocking down Sox2 expression resulted in a markedly decrease in the 
percentage of lung cancer-SP cells and in cells ability to migrate, suggesting that Sox2 
plays an important role in the maintenance of CSC characteristics. [142]. In our study, 
Sox2 gene expression was found to be identical between CRCVB and parental cells and 
down-regulated in CRCVA (-2.2±0.2 FC) (Table 3.3). Therefore, CRCVA and CRCVB 
did not show increased expression of the studied stemness related genes. It may, however, 
be important to assess expression of additional relevant genes. 
Colony-forming assay was performed to evaluate if CRCVB possessed an enhanced 
capacity to generate tumour cell colonies than parental cells. It has already been reported 
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that a cisplatin-resistant population (created by cisplatin exposure) was enriched in stem-
like cells and possessed the ability to generate larger colonies and in a greater number than 
parental cells [139]. However, our study revealed no statistically significant differences 
between the number of tumour colonies formed from CRCVB (63.1 % ± 7.6) and NCI-
H460 parental cells (54.7 % ± 3.6), providing no evidence that the cisplatin-selected 
populations were enriched in stem-like cells.  
 An in vivo assay was also performed to measure the tumourigenecity of NCI-H460 
parental cells and CRCVB, by inoculating three different numbers of cells in the CAM. Six 
chicken embryos were used for each condition, 1x10
6
, 1x10
5 
and 1x10
4 
inoculated cells for 
each population, however not all of them survived until the end of experiment, making it 
difficult to compare the tumourigenicity of both populations. Even so, it was possible to 
note that both populations possessed tumourigenicity ability when 1x10
6
 and 1x10
5 
cells 
were inoculated, however only CRCVB demonstrated ability to generate tumours when 
1x10
4
 cells were inoculated in the CAM (Table 3.2). A tendency for CRCVB cells to 
generate bigger tumours than NCI-H460 parental cells was observed (Figure 3.22), 
although the fact that only one experiment was performed and that there were high levels 
of chicken embryo mortality, compromised the reliability of the obtained data. In order to 
diminish chicken embryo mortality it will be required to decrease the number of days 
between tumour cell inoculation in the CAM and dissection and tissue fixation. So far, 
results obtained indicate that the drug-selected cells may have increased tumourigenic 
capacity (as assessed when 1x10
4
 cells were inoculated in the CAM), and hence stem-like 
cell properties, although additional studies are required to confirm this.  
Bearing this in mind, it seems reasonable to question whether increased ABCG2 
expression found in both cisplatin-resistant cells was associated with a chemoresistance 
mechanism and not related to an indication of stemness properties. Hsieh et al already 
linked the ABCG2 protein as responsible to cisplatin efflux out of the cell and acquired 
resistance towards cisplatin therapy [139].  
 Nevertheless, even if we are not in the presence of cells with stem-like features, the 
results clearly show that chemotherapy enriched a population with higher ability to survive 
than before. Clinically, drug resistance means an important obstacle and reduces the 
survival rate of patients. Platinum-base chemotherapy, especially in combination with 
other drugs, is a common regimen to treat NSCLC [143]. Generally, the mechanism by 
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which cisplatin induces cell death is related to mitochondria mediated apoptosis. To verify 
if anti-apoptotic proteins were involved in the mechanism developed for cells after 
cisplatin exposure, Western blot to Bcl2, Bcl-XL and XIAP were performed. Bcl2 family 
of proteins can both promote (Bax, Bak, Bad, Bid, and Bcl-Xs dependent) or inhibit (Bcl2 
and Bcl-XL) apoptosis through regulation of mitochondrial permeability and cytochrome c 
release [144]. XIAP, a member of IAP family proteins, also possesses the ability to inhibit 
apoptosis pathway by inhibition of caspases 3, 7 and 9 [145]. Both Bcl-2 and Bcl-XL were 
reported before as responsible to represses cell death triggered by cisplatin and to develop 
multidrug-resistance of human ovarian cancer cell lines [146]. Liu et al, in 2011 reported 
that XIAP gene silencing increased apoptosis and restricted the growth of NSCLC cells, 
resulting in increased chemosensitivity of those cells to cisplatin [147]. After Western blot 
analysis, an up-regulation of both Bcl-XL and XIAP proteins were observed in CRVCB 
but no alterations were observed in CRCVA comparing to NCI-H460 parental cells 
(Figures 3.17 and 3.18). No Bcl2 expression differences were detected between CRCVA, 
CRCVB and parental cells (Figure 3.17). It seems that after 2 μM of cisplatin treatment for 
three weeks followed by a drug-free recovery period induced cisplatin resistance and up-
regulation of Bcl-XL and XIAP proteins (Figures 3.17 and 3.18), which probably reflects 
the developed mechanism of those cells to survive the selecting agent. However, when 
cells were exposed to the same conditions but using a lower dose of cisplatin (1 μM), the 
mechanism developed by cells to resist was different. Interestingly, the degree of 
chemoresistance of both cisplatin-resistant populations was found to be exactly the same 
(Figures 3.12, 3.13, respectively). Accounting that both populations possessed multi-drug 
resistance (Figure 3.14) the levels of both Pgp protein and MDR1 gene expression were 
evaluated by western blot and RT-PCR, respectively. It was interesting to note that Pgp 
was 100% up-regulated in CRCVA comparing both to NCI-H460 parental cells and 
CRCVB as determined by Western blot analysis (Figure 3.18). Although Pgp protein has 
never be associated with a mechanism by which cells can have increased resistance to 
cisplatin, it has been considered to exert an important role in resistance to a wide range of 
cytotoxic drugs [148]. RT-PCR to MDR1 gene, which encode to Pgp protein, was found to 
be enhanced in CRCVA (5.9 ± 2.6 FC) when compared to parental cells and even more up-
regulated in CRCVB (10.2 ± 1.8 FC) comparing with parental cells (Table 3.3). The up-
regulation of MDR1 in CRCVB does not correspond to the levels of Pgp as determined by 
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Western blot, in the same population of cells. Pgp protein seemed to be underling the 
mechanism by which CRCVA resists therapy, although its increased presence in CRCVB 
was questionable after known that corresponding gene was up-regulated in those cells. In 
an attempt to investigate the possible role of Pgp protein in both populations, NCI-H460 
parental cells, CRCVA and CRCVB were exposed to cisplatin during 24 hours and the 
expression of Pgp and P53 proteins were than assessed by Western blot. The results 
revealed no Pgp expression differences between NCI-H460 control and treated parental 
cells and CRCVB control and treated cells (Figure 3.19). This may mean that Pgp-
mediated resistance was not activated in CRCVB when cells were exposed to the selecting 
agent. Although, the Pgp was found to be over-expressed in CRCVA treated cells when 
compared to CRCVA untreated cells (Figure 3.19). This suggested that Pgp protein really 
was behind the mechanisms by which these cells resist to therapy, being rapidly up-
regulated after cells contacted with drug. It is, however, important to note that these results 
represent only a sing experience. It was not possible to understand the reason why CRCVB 
possessed enhanced basal levels of MDR1 gene expression but equal levels of Pgp protein 
comparing to parental cells. This means that is not possible to conclude whether Pgp 
protein is responsible for drug efflux. It can be hypothesized that MDR1 mRNA translation 
was being down-regulated, meaning that Pgp protein were not enhanced in CRCVB. It also 
may be possible that a post-transcriptional alteration occurred, such as protein targeting to 
degradation, or even alteration in the epitope recognized by Pgp antibody. In the last case, 
it is possible that Pgp is playing a role in drug efflux out of the cell. P53 expression results 
revealed that after cisplatin treatment the cells activate P53 protein (Figure 3.19). As 
CRCVA and CRCVB were significant more resistant to cisplatin than NCI-H460 parental 
cells, up-regulation of P53 was found to be lower in both resistant population when 
compared to parental cells. 
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5. Conclusions and future perspectives 
Cancer treatment is often hampered by tumor resistance towards chemo and 
radiotherapy, being the CSCs partially responsible for that phenotype. The isolation and 
study of these cells is necessary to understand their properties and regulation, providing a 
way to identify possible targets to render them more sensitive to the chemotherapeutic 
drugs used in the clinic. In this project we aimed to isolate and characterize lung CSC 
populations taking into account the chemoresistance mechanisms of these cells and to 
identify potential therapeutic targets to overcome CSCs chemoresistance.    
It was found that ABCG2 protein is present in about 10-16 % of the entire population 
of NCI-H460 cell line. This allowed the isolation of an  ABCG2
+
 population after 
fluoresce activated cell sorting been performed. Even so, it has been impossible to study 
the putative CSC population isolated because both ABCG2
+
 and ABCG2
-
 cells were 
rapidly capable to ressemble the original population. 
 Cisplatin or doxorubicin exposure during three weeks led to a transient alteration in 
cell morphology in A549 and NCI-H460 cell lines, acquiring a mesenchymal-like 
structure. After chemotherapeutic drugs were withrawn the initial morphology was 
regained. However only in NCI-H460 cells, cisplatin or doxorubicin treatment resulted in 
an acquired resistance towards the selecting agent when compared with the parental cells. 
Indeed, cisplatin treatment induced significant increased resistance towards the selecting 
drug but also resistance to doxorubicin and gemcitabine, although not for 5-FU. 
Cisplatin treatment also enriched a population expressing higher levels of ABCG2 
markers than before. Although, the increased number of cells expressing ABCG2 protein 
after 2 µM of drug exposure seemed to be the only one with biological relevance. It is not 
possible to conclude whether cisplatin was able to enrich a cell population with stem-like 
properties. It would be required to perform additional in vivo assays to measure the 
tumourigenesis of cisplatin-resistant and NCI-H460 parental cells. 
 Different doses of cisplatin treatment in the same cell line select different 
populations, however their capacity to resist to the selecting agent is identical. Anti-
apoptotic proteins, such as Bcl-XL and XIAP, and drug efflux pumps, like MDR1 gene and 
ABCG2, although not Pgp protein, were up-regulated after 2 μM cisplatin treatment. This 
possibly indicates that, in our cisplatin-resistant cells, Bcl-XL and XIAP proteins are 
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responsible for cell survival against cisplatin therapy. Pgp may also be partially responsible 
for the increased drug resistance although only up-regulation was observed in gene 
expression and not in protein expression. A post-transcriptional alteration could have 
affected the epitope recognized by Pgp antibody. Performing the rhodamine-based assay 
would clarify if Pgp function is enhanced in the CRCVB. Rhodamine is a fluorescent Pgp 
substrate widely used as a transporter dye to study multidrug transporters [149]. A more 
elucidative method would be silencing of Bcl-XL, XIAP or Pgp proteins and verify if cells 
reversed their resistant phenotype. Pgp protein and MDR1 gene expression were both 
enhanced after 1μM of cisplatin treatment, but no signal of up-regulation of anti-apoptotic 
proteins were found. P-glycoprotein is normally related with a mechanism by which cells 
efflux drugs, although cisplatin has never been reported to be one of them. Silencing Pgp 
expression in this population and confirm that it sensitized those cells is also the best 
approach to validate Pgp protein as mechanism of cisplatin acquired resistance. 
 Besides Western bolt approaches, it would be extremely important to find out the 
global profile of the proteins present in the parental and resistant cells. 2-D electrophoresis 
is a powerful method used for the analysis of complex protein mixtures extracted from 
cells, tissues, or other biological samples. This technique allows the separation of proteins 
according to two independent properties in two different steps. Thousands of different 
proteins can thus be separated, and information such as the protein pI, the apparent 
molecular weight, and the amount of each protein can be obtained. We have already began 
this kind of experience and using this it would be possible to cross over the protein pattern 
distribution of NCI-H460 parental and resistant cells, which may provide the opportunity 
to discover new proteins involved in regulation of a more aggressive phenotype. 
 In summary, cisplatin treatment enriched resistant lung cancer cells that have 
increased drug resistance. It would be extremely important to understand the mechanisms 
underlying the chemoresistance phenotype in order to be able to overcome tumour 
resistance and relapse. Bcl-XL, XIAP and Pgp proteins appear to be potential therapeutic 
targets to chemosensitize lung cancer tumour cells, although this requires validation in 
future experiments. Therefore, RNA interference studies with siRNAs targeting the 
expression of these genes (independently or in combination) will be performed soon. The 
cells developed during this research may be used as models to develop specific therapeutic 
targets to overcome chemoresistance in lung cancer and improve patient survival.  
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